Agilent (A) 10-Q 7 Sep 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jul. 31, 2016	Aug. 31, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	AGILENT TECHNOLOGIES INC.
Entity Central Index Key	1,090,872
Current Fiscal Year End Date	--10-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		324,384,755
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jul. 31, 2016

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Net revenue:
Products	$ 798	$ 787	$ 2,380	$ 2,346
Services and other	246	227	711	657
Total net revenue	1,044	1,014	3,091	3,003
Costs and expenses:
Cost of products	362	373	1,084	1,122
Cost of services and other	140	128	398	375
Total costs	502	501	1,482	1,497
Research and development	86	79	245	248
Selling, general and administrative	310	290	932	892
Total costs and expenses	898	870	2,659	2,637
Income from operations	146	144	432	366
Interest income	3	2	8	6
Interest expense	(17)	(17)	(53)	(50)
Other income (expense), net	2	(1)	6	15
Income from continuing operations before taxes	134	128	393	337
Provision for income taxes	10	15	57	39
Income from continuing operations	124	113	336	298
Loss from discontinued operations, net of tax benefit of $0, $0, $0 and $(2)	0	(2)	0	(37)
Net income	$ 124	$ 111	$ 336	$ 261
Net income per share - basic
Income from continuing operations	$ 0.38	$ 0.34	$ 1.03	$ 0.89
Loss from discontinued operations	0	(0.01)	0	(0.11)
Net income per share - basic	0.38	0.33	1.03	0.78
Net income per share - diluted
Income from continuing operations	0.38	0.34	1.02	0.89
Loss from discontinued operations	0	(0.01)	0	(0.11)
Net income per share - diluted	$ 0.38	$ 0.33	$ 1.02	$ 0.78
Weighted average shares used in computing net income per share:
Basic (in shares)	325	332	326	334
Diluted (in shares)	328	334	329	336
Cash dividends declared per common share	$ 0.115	$ 0.100	$ 0.345	$ 0.300

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (PARENTHETICAL) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Income tax benefit from discontinued operations	$ 0	$ 0	$ 0	$ (2)

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 124	$ 111	$ 336	$ 261
Other comprehensive income (loss):
Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $(4), $2, $(7) and $4	(5)	1	(11)	7
Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $1, $(2), $0 and $(5)	1	(1)	0	(9)
Foreign currency translation, net of tax expense (benefit) of $(3) $(1), $4 and $(8)	(48)	(66)	41	(337)
Net defined benefit pension cost and post retirement plan costs:
Change in actuarial net loss, net of tax expense of $2, $2, $9 and $6	8	7	29	17
Change in net prior service benefit, net of tax benefit of $(1), $(1), $(7) and $(4)	(2)	(3)	(13)	(8)
Other comprehensive income (loss)	(46)	(62)	46	(330)
Total comprehensive income (loss)	$ 78	$ 49	$ 382	$ (69)

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Other comprehensive income (loss), tax, parenthetical disclosures
Unrealized gain (loss) on derivative instruments, tax	$ (4)	$ 2	$ (7)	$ 4
Amounts reclassified into earnings related to derivative instruments, tax	1	(2)	0	(5)
Foreign currency translation, tax	(3)	(1)	4	(8)
Net defined benefit pension cost and post retirement plan costs, tax
Change in actuarial net loss, tax	2	2	9	6
Change in net prior service benefit, tax	$ (1)	$ (1)	$ (7)	$ (4)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($) $ in Millions	Jul. 31, 2016	Oct. 31, 2015
Current assets:
Cash and cash equivalents	$ 2,199	$ 2,003
Short-term restricted cash and cash equivalents	0	242
Accounts receivable, net	590	606
Inventory	543	541
Other current assets	198	294
Total current assets	3,530	3,686
Property, plant and equipment, net	623	604
Goodwill	2,525	2,366
Other intangible assets, net	442	445
Long-term investments	155	86
Other assets	459	292
Total assets	7,734	7,479
Current liabilities:
Accounts payable	261	279
Employee compensation and benefits	209	221
Deferred revenue	279	258
Short-term debt	235	0
Other accrued liabilities	167	218
Total current liabilities	1,151	976
Long-term debt	1,652	1,655
Retirement and post-retirement benefits	229	264
Other long-term liabilities	356	414
Total liabilities	3,388	3,309
Commitments and Contingencies (Note 12)
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	0	0
Common stock; $0.01 par value; 2 billion shares authorized; 613 million shares at July 31, 2016 and 611 million shares at October 31, 2015, issued	6	6
Treasury stock at cost; 289 million shares at July 31, 2016 and 279 million shares at October 31, 2015	(10,462)	(10,074)
Additional paid-in-capital	9,144	9,045
Retained earnings	6,000	5,581
Accumulated other comprehensive loss	(345)	(391)
Total stockholder's equity	4,343	4,167
Non-controlling interest	3	3
Total equity	4,346	4,170
Total liabilities and equity	$ 7,734	$ 7,479

CONDENSED CONSOLIDATED BALANCE7

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical) - $ / shares	Jul. 31, 2016	Oct. 31, 2015
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	125,000,000	125,000,000
Preferred stock, issued and outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	2,000,000,000	2,000,000,000
Common stock, issued and outstanding (in shares)	613,000,000	611,000,000
Treasury stock at cost, shares (in shares)	289,000,000	279,000,000

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015
Cash flows from operating activities:
Net income	$ 336	$ 261
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	190	193
Share-based compensation	47	43
Deferred taxes	34	(16)
Excess and obsolete inventory related charges	16	20
Other non-cash expense, net	16	13
Changes in assets and liabilities:
Accounts receivable	19	1
Inventory	(11)	(18)
Accounts payable	(27)	(47)
Employee compensation and benefits	(14)	(27)
Other assets and liabilities	(47)	(152)
Net cash provided by operating activities	559	271
Cash flows from investing activities:
Investments in property, plant and equipment	(87)	(71)
Proceeds from sale of property, plant and equipment	0	11
Payments to acquire equity method investments	0	(1)
Loan to equity method investment	3	0
Payment to acquire cost method investment	(80)	0
Payment in exchange for convertible note	(1)	(2)
Change in restricted cash and cash equivalents, net	245	1
Proceeds from sale of investment securities	1	0
Proceeds from divestitures	0	3
Acquisitions of businesses and intangible assets, net of cash acquired	(235)	(66)
Net cash used in investing activities	(160)	(125)
Cash flows from financing activities:
Issuance of common stock under employee stock plans	59	57
Cash paid to tax authorities for withheld shares from employees	(6)	(12)
Payment of dividends	(112)	(100)
Net transfer of cash and cash equivalents to Keysight	0	(734)
Proceeds from revolving credit facility	255	0
Repayment of revolving credit facility	(20)	0
Treasury stock repurchases	(388)	(267)
Net cash used in financing activities	(212)	(1,056)
Effect of exchange rate movements	9	(43)
Net increase (decrease) in cash and cash equivalents	196	(953)
Change in cash and cash equivalents related to discontinued operations	0	810
Cash and cash equivalents at beginning of period	2,003	2,218
Cash and cash equivalents at end of period	2,199	2,075
Supplemental cash flow information:
Income tax payments, net	54	121
Interest payments	$ 66	$ 64

OVERVIEW, BASIS OF PRESENTATION

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes)	9 Months Ended
	Jul. 31, 2016
Accounting Policies [Abstract]
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters. Basis of Presentation . We have prepared the accompanying financial data for the three and nine months ended July 31, 2016 and 2015 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2015 . In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of July 31, 2016 and October 31, 2015 , condensed consolidated statement of comprehensive income (loss) for the three and nine months ended July 31, 2016 and 2015 , condensed consolidated statement of operations for the three and nine months ended July 31, 2016 and 2015 , and condensed consolidated statement of cash flows for the nine months ended July 31, 2016 and 2015 . Revision of Services and Other and Product Net Revenues and related Cost of Sales. In 2015, we revised amounts shown in our condensed consolidated statement of operations to more accurately reflect the character of items delivered to customers. Our diagnostic and genomics segment identified a stream of service revenues that had been presented as product revenue in the prior year. We have now revised prior year's presentation to show the revenue within services and other. The cost of sales associated with these newly identified service revenues has also been revised to align with the new presentation. For the three and nine months ended July 31, 2015 services and other revenue increased $11 million and $26 million and services and other cost of sales increased $7 million and $18 million with corresponding reductions in product revenue and cost of sales. These corrections to the classifications are not considered to be material to current or prior periods and had no impact to our results of operations previously reported in our condensed consolidated statement of operations. Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, share-based compensation, retirement and post-retirement plan assumptions and accounting for income taxes. Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). The company evaluates its investments in privately held companies on an ongoing basis. We have determined that as of July 31, 2016 there were no VIE’s required to be consolidated in the company’s consolidated financial statements because we do not have a controlling financial interest in any of the VIE’s that we have invested in nor are we the primary beneficiary. We account for these investments under either the equity or cost method, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. As of July 31, 2016 , the carrying value of our investments in VIE’s was $101 million with a maximum exposure of $108 million which includes our loans to our investments. The investments are included on the long term investments line of the condensed consolidated balance sheet. During the nine months ended July 31, 2016 , Agilent made a preferred stock investment in Lasergen for $80 million . Agilent’s initial ownership stake was 48 percent and we have also joined the board of Lasergen and signed a collaboration agreement. We have the option to acquire all of the remaining shares of Lasergen until March 2, 2018, for additional consideration of $105 million . Lasergen is a VIE, however, we do not consolidate the entity in our financial statements because we do not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance. Because of the nature of the preferred stock of Lasergen that we own, we account for this investment under the cost method. As of July 31, 2016 , both the carrying value and maximum exposure of the Lasergen investment was $80 million . The maximum exposure is equal to the carrying value because we do not have future funding commitments. Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments is determined using quoted market prices for those securities when available. For those long-term equity investments accounted for under the cost or equity method, their carrying value approximates their estimated fair value. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. The fair value of our long-term debt, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately $102 million and $30 million as of July 31, 2016 and October 31, 2015 , respectively. The change in the excess of fair value over carrying value in the nine months ended July 31, 2016 is due to fluctuations in market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 9, "Fair Value Measurements" for additional information on the fair value of financial instruments. Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e. greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required. The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers. If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. In fiscal year 2015, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a quantitative test for goodwill impairment of the three reporting units, as of September 30, 2015. Based on the results of our testing, the fair value of these reporting units are greater than their respective carrying values. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the three and nine months ended July 31, 2016 and 2015 . Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years . In-process research and development ("IPR&D") is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's condensed consolidated statement of operations in the period it is abandoned. Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e. greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2015. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of these indefinite-lived intangible assets is greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets is indicated. During the three and nine months ended July 31, 2016 , we recorded an impairment of $4 million due to the announced cancellation of a certain IPR&D project. There were no impairments in the three and nine months ended July 31, 2015 .

REVISION OF PRIOR PERIOD FINANC

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Notes)	9 Months Ended
	Jul. 31, 2016
Income Tax Disclosure [Abstract]
Accounting Changes and Error Corrections [Text Block]	2. REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS During the years ended October 31, 2014 and 2015, the company identified and recorded various out of period income tax adjustments. We determined that the errors were not material to the previously issued financial statements and disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2014 or for any quarterly periods included therein or through our Quarterly Report on Form 10-Q for the nine months ended July 31, 2015. However, as a result of the company presenting continuing operations and discontinued operations for the first time in our Annual Report on Form 10-K for the year ended October 31, 2015, we determined that the effect of the errors is significant to our financial results for the year ending October 31, 2014 and 2013. Accordingly, we revised our historical financial statements presented in our Form 10-K for the year ended October 31, 2015. For the three and nine months ended July 31, 2016 , we are presenting comparative fiscal 2015 quarterly information. The fiscal 2015 results for the three and nine months ended July 31, 2015 have been revised to reflect the quarterly impact of the out of period adjustments described above. For the three months ended July 31, 2015 the following out of period adjustments were included in the as-reported column in the revision adjustment table and have been removed in the adjustments column: $8 million of tax expense related to the correction of the U.S. deferred tax liability for unremitted earnings of foreign subsidiaries. In addition to the aforementioned, for the nine months ended July 31, 2015 , the following out of period adjustments were included in the as-reported column in the revision adjustment table and have been removed in the adjustments column: $4 million of tax expense related to the increase of foreign deferred tax liabilities for a prior year, $13 million of tax benefit from the reduction in deferred tax liabilities due to tax rate changes in Denmark occurring in a prior year and $4 million of tax expense attributable to an error discovered on a prior year U.S. tax return. Three Months Ended July 31, 2015 As Reported Adjustments As Revised (in millions, except per share data) Income from continuing operations before taxes $ 128 $ 128 Provision for income taxes 23 (8 ) 15 Income from continuing operations 105 113 Loss from discontinued operations, net of tax benefit of $0 million (2 ) (2 ) Net Income $ 103 $ 8 $ 111 Net income per share - basic Income from continuing operations $ 0.32 $ 0.34 Loss from discontinued operations (0.01 ) (0.01 ) Net income per share - basic $ 0.31 $ 0.33 Net income per share - diluted Income from continuing operations $ 0.31 $ 0.34 Loss from discontinued operations — (0.01 ) Net income per share - diluted $ 0.31 $ 0.33 Total comprehensive income $ 41 $ 8 $ 49 Nine Months Ended July 31, 2015 As Reported Adjustments As Revised (in millions, except per share data) Income from continuing operations before taxes $ 337 $ 337 Provision for income taxes 42 (3 ) 39 Income from continuing operations 295 298 Loss from discontinued operations, net of tax benefit of $(2) (37 ) (37 ) Net Income $ 258 $ 3 $ 261 Net income per share - basic Income from continuing operations $ 0.88 $ 0.89 Loss from discontinued operations (0.11 ) (0.11 ) Net income per share - basic $ 0.77 $ 0.78 Net income per share - diluted Income from continuing operations $ 0.88 $ 0.89 Loss from discontinued operations (0.11 ) (0.11 ) Net income per share - diluted $ 0.77 $ 0.78 Total comprehensive loss $ (72 ) $ 3 $ (69 ) The adjustments resulted in the following revisions to our condensed consolidated statement of cash flow. Nine Months Ended July 31, 2015 As Reported Adjustments As Revised (1) (in millions) Net income $ 258 $ 3 $ 261 Deferred taxes $ (15 ) $ (1 ) $ (16 ) Changes in assets and liabilities: Other assets and liabilities $ (162 ) $ (2 ) $ (164 ) Net cash provided by operating activities $ 254 $ — $ 254 ___________________________________ (1) The presentation above of certain amounts from the consolidated statement of cash flow for the nine months ended July 31, 2015 does not include the adjustments related to the early adoption of new guidance which have also been made in the third quarter of fiscal year 2016. See Note 3 "New Accounting Pronouncements" for additional information.

NEW ACCOUNTING PRONOUNCEMENTS (

NEW ACCOUNTING PRONOUNCEMENTS (Notes)	9 Months Ended
	Jul. 31, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
NEW ACCOUNTING PRONOUNCEMENTS	3. NEW ACCOUNTING PRONOUNCEMENTS There were no changes to the new accounting pronouncements as described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2015 except for the following: In March 2016, the Financial Accounting Standards Board (“FASB”) issued amendments that change the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The standard also allows us to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on our cash flows statement, and provides an accounting policy election to account for forfeitures as they occur. The amendments also remove the requirement to delay the recognition of an excess tax benefit until it reduces current taxes payable. Under the new guidance the benefit will be recorded when it arises with a cumulative effect adjustment to opening retained earnings for previously unrecognized benefits. The new guidance is effective for us beginning November 1, 2017, with early adoption permitted. We elected to early adopt the new guidance in the third quarter of fiscal year 2016, on a retrospective basis, which requires us to reflect any adjustments as of November 1, 2015, the beginning of the annual period that includes the interim period of adoption. The impact of adoption on previously reported quarterly results was the recognition of tax shortfalls of $2 million in our provision for income taxes for the first quarter of fiscal year 2016. Additional amendments to the accounting for income taxes on previously reported quarterly results was the recognition of the windfall tax benefits as a cumulative effect adjustment to opening retained earnings of $195 million together with an increase in deferred tax assets included in other assets of $97 million , an increase in additional paid in capital of $4 million , a reduction in other accrued liabilities of $1 million and a decrease of $99 million in other long term liabilities. There was no impact from minimum statutory withholding tax requirements to retained earnings as of November 1, 2015. We have elected to continue to estimate forfeitures expected to occur to determine the amount of compensation cost to be recognized in each period. The adoption of the new guidance did not have a significant impact on the calculation of diluted weighted average shares. The impact of the adoption on our previously reported quarterly results for fiscal year 2016 follows: Three Months Ended January 31, 2016 Six Months Ended April 30, 2016 As Reported As Adjusted As As (in millions, except per share amounts) Condensed Consolidated Statement of Operations: Provision for income taxes $ 19 $ 21 $ 45 $ 47 Net income $ 123 $ 121 $ 214 $ 212 Net income per share - Basic $ 0.37 $ 0.37 $ 0.65 $ 0.65 Net income per share - Diluted $ 0.37 $ 0.36 $ 0.65 $ 0.64 Weighted average shares used in computing net income per share - Diluted 332 332 330 330 We elected to apply the presentation requirements for cash flows related to excess tax benefits and employee taxes paid for withheld shares retrospectively to all periods presented which resulted in an increase to both net cash from operations and net cash used in financing of $1 million and $6 million for the three and nine months ended July 31, 2016, respectively. The presentation requirements for cash flows also impacted our previously reported quarterly condensed consolidated statement of cash flows for fiscal years 2016 and 2015 as follows: Three Months Ended Six Months Ended As As Adjusted As As Adjusted (in millions) Condensed Consolidated Statement of Cash Flows: Net cash provided by operating activities $ 104 $ 111 $ 360 $ 365 Net cash used in financing activities $ (132 ) $ (139 ) $ (102 ) $ (107 ) Three Months Ended January 31, 2015 Six Months Ended April 30, 2015 Nine Months Ended July 31, 2015 As As Adjusted As As Adjusted As (1) As Adjusted (in millions) Condensed Consolidated Statement of Cash Flows: Net cash provided by (used in) operating activities $ (20 ) $ (9 ) $ 163 $ 175 $ 254 $ 271 Net cash used in financing activities $ (828 ) $ (839 ) $ (929 ) $ (941 ) $ (1,039 ) $ (1,056 ) (1) See Note 2, "Revision of Prior Period Financial Statements" for additional information. January 31, 2016 April 30, 2016 As As As As (in millions) Condensed Consolidated Balance Sheet: Other assets $ 242 $ 353 $ 339 $ 436 Other accrued liabilities $ 169 $ 168 $ 188 $ 187 Other long-term liabilities $ 412 $ 329 $ 446 $ 347 Additional paid-in-capital $ 9,085 $ 9,087 $ 9,103 $ 9,107 Retained earnings $ 5,666 $ 5,859 $ 5,720 $ 5,913 In August 2016, the FASB issued amendments to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The amendments are effective for us beginning November 1, 2018 and interim periods in the following year. Early adoption is permitted. If we decide to early adopt the amendments, we will be required to adopt all of the amendments in the same period. We are evaluating the potential impact of the amendments on our consolidated statement of cash flows and disclosures. In March 2016, the FASB issued amendments to simplify the transition to the equity method of accounting. The amendments require that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor’s previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The amendments are effective for us beginning November 1, 2017 and interim periods in the following year. We are evaluating the potential impact of this amendment on our consolidated financial statements. In February 2016, the FASB issued guidance which amends the existing accounting standards for leases. Consistent with existing guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification. Under the new guidance, a lessee will be required to recognize right-of-use assets and lease liabilities on the balance sheet. The new guidance is effective for us beginning November 1, 2020, and interim periods in the following year. Early adoption of this guidance is permitted and we will be required to adopt using a modified retrospective approach. We are evaluating the timing and the impact of adopting this guidance on our consolidated financial statements and disclosures. In January 2016, the FASB issued amendments to address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The standard requires entities to measure equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in fair value in net income. The provisions under this amendment are effective for us beginning November 1, 2018, and for interim periods in the following year and early adoption is not permitted. We are evaluating the impact of adopting this guidance to our consolidated financial statements. In November 2015, the FASB issued guidance to simplify accounting for deferred taxes. Beginning on November 1, 2017 and including the interim periods following that date, we will be required to present all deferred tax balances as non-current. Existing GAAP guidance requires us to record deferred tax balances as either current or non-current in accordance with the classification of the underlying attributes. Early adoption of this guidance is permitted and may be applied either prospectively or retrospectively to all periods presented. We adopted this guidance at the end of the period ended April 30, 2016 prospectively and therefore, the July 31, 2016 condensed consolidated balance sheet reflects the new disclosure requirements but prior periods have not been adjusted. In May 2014, the FASB issued amendments to the accounting guidance related to revenue recognition. The objective of the amendments was to significantly enhance comparability and clarify principles of revenue recognition practices across entities, industries, jurisdictions and capital markets. In March 2016, the FASB clarified the implementation guidance on principal versus agent considerations. In April 2016, the FASB clarified certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB provided additional guidance related to disclosure of remaining performance obligations, as well as other amendments to guidance on collectibility, non-cash consideration and the presentation of sales and other similar taxes collected from customers. The amendments are effective for us beginning November 1, 2018. Early adoption is permitted for us beginning November 1, 2017. The company is currently assessing the potential impact of these amendments on our consolidated financial statements. Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

SHARE-BASED COMPENSATION (Notes

SHARE-BASED COMPENSATION (Notes)	9 Months Ended
	Jul. 31, 2016
Share-based Compensation [Abstract]
SHARE-BASED COMPENSATION	4. SHARE-BASED COMPENSATION Agilent accounts for share-based awards in accordance with the provisions of the authoritative accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our employee stock purchase plan (“ESPP”) and performance share awards granted to selected members of our senior management under the long-term performance plan (“LTPP”) based on estimated fair values. Participants in the LTPP are entitled to receive unrestricted shares of the company's stock after the end of a three-year period, if specified performance targets are met. Certain LTPP awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the Total Stockholders’ Return (“TSR”) set at the beginning of the performance period. Effective November 1, 2015, the Compensation Committee of the Board of Directors approved another type of performance stock award, for the company's executive officers and other key employees. Participants in this program are also entitled to receive unrestricted shares of the company's stock after the end of a three-year period, if specified performance targets based on Operating Margin (“OM”) over the three- year period are met. All LTPP awards granted after November 1, 2015, are subject to a one year post-vest holding period. Based on the performance metrics the final LTPP award may vary from zero to 200 percent of the target award. The maximum award value cannot exceed 300 percent of the grant date target value. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met. The impact on our results for share-based compensation was as follows: Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 2016 2015 (in millions) Cost of products and services $ 2 $ 2 $ 11 $ 9 Research and development 1 1 4 4 Selling, general and administrative 8 7 33 31 Total share-based compensation expense $ 11 $ 10 $ 48 $ 44 At July 31, 2016 and October 31, 2015 , there was no share-based compensation capitalized within inventory. The following assumptions were used to estimate the fair value of the options and LTPP grants. Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 2016 2015 Stock Option Plans: Weighted average risk-free interest rate — — — 1.7 % Dividend yield — — — 1 % Weighted average volatility — — — 28 % Expected life — — — 5.5yrs LTPP: Volatility of Agilent shares 24% 25% 24 % 25 % Volatility of selected peer-company shares 14%-50% 12%-57% 14%-50% 12%-57% Price-wise correlation with selected peers 35% 37% 35 % 37 % The fair value of share-based awards for employee stock option awards was estimated using the Black-Scholes option pricing model. Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation model. Both the Black-Scholes and Monte Carlo simulation fair value models require the use of highly subjective and complex assumptions, including the option’s expected life and the price volatility of the underlying stock. Due to the separation of Keysight on November 1, 2014, expected volatility for grants of options in fiscal 2015 was based on a 5.5 year average historical stock price volatility of a group of our peer companies. For the volatility of our 2016 and 2015 LTPP (TSR) grants, we used the 3 year average historical stock price volatility of a group of our peer companies. We believe our historical volatility prior to the separation of Keysight is no longer relevant to use. For the grants of options and LTPP (TSR) prior to November 1, 2014, the expected stock price volatility assumption was determined using the historical volatility of Agilent’s stock over the most recent historical period equivalent to the expected life of the stock options and LTPP (TSR). In developing our estimated life assumption of our employees' stock options of 5.5 years, we considered the separation of Keysight and the historical option exercise behavior for our executive employees who were granted the majority of the options in the annual grants made which we believe is representative of future behavior. No stock options were granted during the three and nine months ended July 31, 2016 . The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the price at purchase and uses the purchase date to establish the fair market value. The estimated fair value of restricted stock unit and LTPP (OM) awards is determined based on the market price of Agilent’s common stock on the date of grant adjusted for expected dividend yield. The compensation cost for LTPP (OM) reflects the cost of awards that are probable to vest at the end of the performance period. All awards granted in 2016 to our senior management employees have a one year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model. The model calculates the potential lost value if the employee were able to sell the shares during the lack of marketability period, instead of being required to hold the shares. The model used the 3 year average historical stock price volatility of a group of our peer companies and an expected dividend yield to compute the discount. The grants made during 2016 have a discount of 5.5 percent while computing the fair value. In the third quarter of fiscal year 2016, the company elected to early adopt new guidance that changes the accounting for certain aspects of share-based payments to employees. For additional details related to the new guidance see Note 3, "New Accounting Pronouncements."

INCOME TAXES (Notes)

INCOME TAXES (Notes)	9 Months Ended
	Jul. 31, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	5. INCOME TAXES The company’s effective tax rate from continuing operations was 7.5 percent and 14.5 percent for the three and nine months ended July 31, 2016 , respectively. The company’s effective tax rate from continuing operations was 11.7 percent and 11.6 percent for the three and nine months ended July 31, 2015 , respectively. The income tax expense from continuing operations was $10 million and $57 million for the three and nine months ended July 31, 2016 , respectively. The income tax expense from continuing operations was $15 million and $39 million for the three and nine months ended July 31, 2015 , respectively. The income tax provision from continuing operations for the three and nine months ended July 31, 2016 included net discrete tax benefits of $6 million and $9 million , respectively. The net discrete tax benefit for the three months ended July 31, 2016, included an out-of-period correcting tax benefit of $11 million associated with a true-up of deferred tax liability for unremitted foreign earnings that should have been recorded in the third quarter of fiscal year 2015 and $5 million net expense related to other discrete items. In addition to the aforementioned, the net discrete tax benefit for the nine months ended July 31, 2016, included $5 million of tax benefit for the extension of the U.S. research and development tax credit attributable to the company's prior fiscal year, $6 million of tax expense related to the curtailment gain recognized with respect to the U.S. retirement plan and Supplemental Benefits Plan, $8 million tax benefit related to the realization of tax credits that reduce the deferred tax liability for unremitted foreign earnings, and a net $4 million of other discrete tax expense primarily related to return-to-provision true-ups, including an out-of-period adjustment recorded in the second quarter of fiscal year 2016 of $5 million of expense in Germany. The out-of-period corrections were determined to be immaterial to the previously issued and current period financial statements. The income tax provision from continuing operations for the three and nine months ended July 31, 2015 included net discrete expense of $1 million and benefit of $15 million , respectively. The net discrete tax expense for the three months ended July 31, 2015 included $1 million of tax expense related primarily to interest accruals for uncertain tax positions. In addition to the aforementioned, the net discrete tax benefit for the nine months ended July 31, 2015 included $16 million of tax benefit related to the de-registration of certain foreign branches, $6 million of tax benefit for the extension of the U.S. research and development tax credit attributable to the company's prior fiscal year and $6 million of other discrete tax expense primarily related to the accrual of interest expense associated with uncertain tax positions and return to provision adjustments. In the third quarter of fiscal 2016, the company elected to early adopt Accounting Standard Update (“ASU”) 2016-09 “Improvements to Employees Share-Based Payment Accounting”. For details related to the adoption of this new accounting standard update see Note 3, “New Accounting Pronouncements”. In the three and nine months ended July 31, 2016 we recorded $3 million and $1 million of tax benefit, respectively, in respect of share based awards. In the U.S., tax years remain open back to the year 2012 for federal income tax purposes and the year 2000 for significant states. On September 22, 2015, we reached an agreement with the Internal Revenue Service ("IRS") for the tax years 2008 through 2011. During the first quarter of 2016, we made a payment of approximately $9 million of tax plus interest as part of closing the exam. In 2015, we reclassified a portion of other long-term liabilities to other accrued liabilities related to uncertain tax positions of continuing operations that we expected to pay within the next twelve months. This amount was partially offset by a prepaid tax account of approximately $3 million that the IRS allowed as an offset to the $12 million in incremental taxes. The settlement resulted in the recognition, within the continuing operations, of previously unrecognized tax benefits of $119 million , offset by a tax liability on foreign distributions of approximately $99 million principally related to the repatriation of foreign earnings. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2003. With these jurisdictions and the U.S., it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits. On July 27, 2015, the U.S. Tax Court issued an opinion in Altera Corp. v. Commissioner related to the treatment of stock-based compensation expense in an intercompany cost-sharing arrangement. A final decision was entered by the U.S. Tax Court on December 1, 2015. At this time, the U.S. Department of the Treasury has not withdrawn the requirement from its regulations to include stock-based compensation in an intercompany cost-sharing arrangement. The IRS notified the U.S. Court of Appeals for the Ninth Circuit on February 19, 2016 of its intent to appeal the Tax Court's decision in the case. We concluded that no adjustment to our consolidated financial statements is appropriate at this time due to the uncertainties with respect to the ultimate resolution of this case.

NET INCOME PER SHARE (Notes)

NET INCOME PER SHARE (Notes)	9 Months Ended
	Jul. 31, 2016
Earnings Per Share [Abstract]
NET INCOME PER SHARE	6. NET INCOME PER SHARE The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below: Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 (As Revised) 2016 2015 (As Revised) (in millions) Numerator: Income from continuing operations $ 124 $ 113 $ 336 $ 298 Loss from discontinued operations — (2 ) — (37 ) Net income $ 124 $ 111 $ 336 $ 261 Denominator: Basic weighted-average shares 325 332 326 334 Potential common shares— stock options and other employee stock plans 3 2 3 2 Diluted weighted-average shares 328 334 329 336 The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards. We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. For the three and nine months ended July 31, 2016 , zero and 1.1 million options to purchase shares were excluded from the calculation of diluted earnings per share, respectively. For the three and nine months ended July 31, 2015 , 1.2 million and 856,900 options to purchase shares were excluded from the calculation of diluted earnings per share, respectively. In addition, we exclude from the calculation of diluted earnings per share stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value were greater than the average market price of our common stock because their effect would also be anti-dilutive. For the three and nine months ended July 31, 2016 , zero and 306,100 additional shares were excluded from the calculation of diluted earnings per share, respectively. For the three and nine months ended July 31, 2015 , 80,900 and 487,100 additional shares were excluded from the calculation of diluted earnings per share, respectively.

INVENTORY (Notes)

INVENTORY (Notes)	9 Months Ended
	Jul. 31, 2016
Inventory, Net [Abstract]
INVENTORY	7. INVENTORY July 31, October 31, (in millions) Finished goods $ 351 $ 362 Purchased parts and fabricated assemblies 192 179 Inventory $ 543 $ 541

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)	9 Months Ended
	Jul. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	8. GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the nine months ended July 31, 2016 : Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2015 $ 650 $ 1,234 $ 482 $ 2,366 Foreign currency translation impact 5 14 3 22 Goodwill arising from acquisitions 137 — — 137 Goodwill as of July 31, 2016: $ 792 $ 1,248 $ 485 $ 2,525 The components of other intangibles as of July 31, 2016 and October 31, 2015 are shown in the table below: Purchased Other Intangible Assets Gross Carrying Amount Accumulated Amortization Net Book Value (in millions) As of October 31, 2015: Purchased technology $ 746 $ 476 $ 270 Trademark/Tradename 141 50 91 Customer relationships 230 168 62 Total amortizable intangible assets 1,117 694 423 In-Process R&D 22 — 22 Total $ 1,139 $ 694 $ 445 As of July 31, 2016: Purchased technology $ 830 $ 553 $ 277 Backlog 1 1 — Trademark/Tradename 151 59 92 Customer relationships 263 208 55 Total amortizable intangible assets 1,245 821 424 In-Process R&D 18 — 18 Total $ 1,263 $ 821 $ 442 On November 1, 2015, we acquired Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics, for $242 million . As a result, we recorded additions to goodwill of $137 million and additions to other intangible assets of $118 million during the nine months ended July 31, 2016 . During the nine months ended July 31, 2016 , other intangible assets increased $3 million , due to the impact of foreign exchange translation. In the three and nine months ended July 31, 2016, we recorded $4 million of impairments of other intangible assets related to the cancellation of an in-process research and development project. In the three and nine months ended July 31, 2015, there were no impairments of other intangible assets. Amortization expense of intangible assets was $37 million and $120 million for the three and nine months ended July 31, 2016 , respectively. Amortization expense of intangible assets was $38 million and $119 million for the three and nine months ended July 31, 2015 , respectively. Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2016 and for each of the five succeeding fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) Remainder of 2016 $ 32 2017 $ 112 2018 $ 82 2019 $ 58 2020 $ 48 2021 $ 35 Thereafter $ 57

FAIR VALUE MEASUREMENTS (Notes)

FAIR VALUE MEASUREMENTS (Notes)	9 Months Ended
	Jul. 31, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	9. FAIR VALUE MEASUREMENTS The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value: Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data. Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis as of July 31, 2016 were as follows: Fair Value Measurement at July 31, 2016 Using July 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,398 $ 1,398 $ — $ — Derivative instruments (foreign exchange contracts) 5 — 5 — Long-term Trading securities 31 31 — — Total assets measured at fair value $ 1,434 $ 1,429 $ 5 $ — Liabilities: Short-term Derivative instruments (foreign exchange and interest rate swap contracts) $ 22 $ — $ 22 $ — Long-term Deferred compensation liability 31 — 31 — Total liabilities measured at fair value $ 53 $ — $ 53 $ — Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2015 were as follows: Fair Value Measurement at October 31, 2015 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,411 $ 1,411 $ — $ — Derivative instruments (foreign exchange contracts) 4 — 4 — Long-term Trading securities 35 35 — — Total assets measured at fair value $ 1,450 $ 1,446 $ 4 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Long-term Deferred compensation liability 35 — 35 — Total liabilities measured at fair value $ 40 $ — $ 40 $ — Our money market funds and trading securities investments are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable. Trading securities, which is comprised of mutual funds, bonds and other similar instruments, and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive loss within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income. Impairment of Investments. There were no impairments of investments for the three and nine months ended July 31, 2016 and 2015 . Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis For the three and nine months ended July 31, 2016 , long-lived assets held and used relating to IPR&D projects with a carrying amount of $4 million were written down to their fair value of zero, resulting in an impairment charge of $4 million, which was included in net income. For the three and nine months ended July 31, 2015 , there were no impairments of long-lived assets held and used. For the three and nine months ended July 31, 2016 and 2015 , there were no impairments of long-lived assets held for sale.

DERIVATIVES (Notes)

DERIVATIVES (Notes)	9 Months Ended
	Jul. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES	10. DERIVATIVES We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts, purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates. Fair Value Hedges We are exposed to interest rate risk due to the mismatch between the interest expense we pay on our loans at fixed rates and the variable rates of interest we receive from cash, cash equivalents and other short-term investments. We have issued long-term debt in U.S. dollars at fixed interest rates based on the market conditions at the time of financing. The fair value of our fixed rate debt changes when the underlying market rates of interest change, and, in the past, we have used interest rate swaps to change our fixed interest rate payments to U.S. dollar LIBOR-based variable interest expense to match the floating interest income from our cash, cash equivalents and other short term investments. As of July 31, 2016 , all interest rate swap contracts had either been terminated or had expired. On November 25, 2008, we terminated two interest rate swap contracts associated with our 2017 senior notes that represented the notional amount of $400 million . On October 20, 2014 we prepaid $500 million out of $600 million principal of our 2017 senior notes and fully amortized the associated proportionate deferred gain to other income (expense). The remaining gain to be amortized related to the $100 million of 2017 senior notes at July 31, 2016 was $1 million . On August 9, 2011, we terminated five interest rate swap contracts related to our 2020 senior notes that represented the notional amount of $500 million . The remaining gain to be amortized at July 31, 2016 was $16 million . All deferred gains from terminated interest rate swaps are being amortized over the remaining life of the respective senior notes. Cash Flow Hedges We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. Changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in other income (expense) each period. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified to cost of sales in the condensed consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense) in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense) in the condensed consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in other income (expense) over the life of the option contract. Ineffectiveness in the three and nine months ended July 31, 2016 and 2015 was not significant. For the three and nine months ended July 31, 2016 and 2015 gains and losses recognized in other income (expense) due to de-designation of cash flow hedge contracts were not significant. In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 10, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at July 31, 2016 was $2 million . In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments associated with the planned issuance of debt in the form of senior notes later this fiscal year. The contract term allows us to hedge the interest rate risk and lock-in a benchmark rate on our anticipated debt issuance. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance. The changes in fair value of these derivative instruments will be recognized in accumulated other comprehensive income (loss). If the benchmark interest rates increase between the date of entry into the swap arrangement and termination, then the fair value of the swap increases. Conversely if benchmark interest rates decrease between the date of entry into the swap arrangement and termination, then the fair value of the swap decreases. For the three and nine months ended July 31, 2016 , the change in fair value of the swap was classified as a loss in accumulated other comprehensive income (loss) of $11 million and $14 million , respectively. Amounts associated with these cash flow hedges will be reclassified to interest expense in the condensed consolidated statement of operations when the forecasted future interest payments on the senior notes occur. The coupon (interest rate payable) of the senior notes at issue will be comprised of the benchmark interest rate (which has been fixed by the swap) and the yield spread. Other Hedges Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative are recognized in other income (expense) in the condensed consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities. Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties. A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of July 31, 2016 , was $19 million . The credit-risk-related contingent features underlying these agreements had not been triggered as of July 31, 2016 . There were 73 foreign exchange forward contracts open as of July 31, 2016 and designated as cash flow hedges. There were 156 foreign exchange forward contracts open as of July 31, 2016 not designated as hedging instruments. The aggregated notional amounts by currency and designation as of July 31, 2016 were as follows: Derivatives Designated as Cash Flow Hedges Derivatives Not Designated as Hedging Instruments Forward Contracts USD Forward Contracts USD Forward Contracts DKK Currency Buy/(Sell) Buy/(Sell) Buy/(Sell) (in millions) Euro $ (46 ) $ 105 $ (64 ) British Pound (34 ) — (4 ) Canadian Dollar (26 ) — (2 ) Australian Dollar 4 12 (4 ) Malaysian Ringgit — (2 ) — Japanese Yen (75 ) 21 (3 ) American Dollar — — 50 Other (6 ) 31 (15 ) Totals $ (183 ) $ 167 $ (42 ) Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of July 31, 2016 and October 31, 2015 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location July 31, October 31, Balance Sheet Location July 31, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange forward contracts $ 3 $ 2 $ 7 $ 1 Interest rate swap contracts — — 14 — Other current assets $ 3 $ 2 Other accrued liabilities $ 21 $ 1 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 2 $ 2 Other accrued liabilities $ 1 $ 4 Total derivatives $ 5 $ 4 $ 22 $ 5 The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 2016 2015 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive income (loss) $ 2 $ 3 $ (4 ) $ 11 Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales $ (2 ) $ 3 $ — $ 14 Interest rate swap contracts: Loss recognized in accumulated other comprehensive income (loss) $ (11 ) $ — $ (14 ) $ — Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense) $ (2 ) $ (3 ) $ 3 $ (20 ) The estimated amount of existing net loss at July 31, 2016 that is expected to be reclassified from other comprehensive income (loss) to cost of sales within the next twelve months is $3 million .

RETIREMENT PLANS AND POST RETIR

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes)	9 Months Ended
	Jul. 31, 2016
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	1. RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Components of net periodic costs. For the three and nine months ended July 31, 2016 and 2015 , our net pension and post retirement benefit costs were comprised of the following: Pensions U.S. Plans Non-U.S. Plans U.S. Post Retirement Benefit Plans Three Months Ended July 31, 2016 2015 2016 2015 2016 2015 (in millions) Service cost—benefits earned during the period $ — $ 6 $ 5 $ 4 $ — $ 1 Interest cost on benefit obligation 4 3 4 6 1 1 Expected return on plan assets (6 ) (7 ) (11 ) (10 ) (2 ) (2 ) Amortization: Actuarial losses — 2 7 6 3 1 Prior service cost — (1 ) — — (3 ) (3 ) Total net plan costs $ (2 ) $ 3 $ 5 $ 6 $ (1 ) $ (2 ) Curtailments and settlements $ — Pensions U.S. Plans Non-U.S. U.S. Post Retirement Nine Months Ended July 31, 2016 2015 2016 2015 2016 2015 (in millions) Service cost—benefits earned during the period $ 12 $ 18 $ 14 $ 12 $ — $ 3 Interest cost on benefit obligation 11 10 12 18 3 3 Expected return on plan assets (18 ) (21 ) (33 ) (31 ) (5 ) (6 ) Amortization: Actuarial losses 2 4 21 19 8 3 Prior service cost (2 ) (3 ) — — (8 ) (9 ) Total net plan costs $ 5 $ 8 $ 14 $ 18 $ (2 ) $ (6 ) Curtailment and settlements $ (16 ) We made no contribution to our U.S. defined benefit plans during both the three and nine months ended July 31, 2016 . We contributed $6 million and $19 million to our non-U.S. defined benefit plans during the three and nine months ended July 31, 2016 , respectively. We made no contribution to our U.S. defined benefit plans during the three months ended July 31, 2015. We contributed $15 million to our U.S. defined benefit plans during the nine months ended July 31, 2015 . We contributed $9 million and $20 million to our non-U.S. defined benefit plans during the three and nine months ended July 31, 2015 , respectively. We do not expect to contribute to our U.S. defined benefit plans during the remainder of 2016 and we expect to contribute $6 million to our non-U.S. defined benefit plans during the remainder of 2016 . Plan Amendments. During the three months ended January 31, 2016, we made changes to our U.S. Retirement Plan and Supplemental Benefits Retirement Plan ("U.S. Plans"). Effective April 30, 2016, benefit accruals under the U.S. Plans were frozen. Any pension benefit earned in the U.S. Plans through April 30, 2016 remained fully vested, and there were no additional benefit accruals after April 30, 2016. In addition, active employees who have not met the eligibility requirement for the Retiree Medical Account (RMA) under the U.S. Post Retirement Benefit Plan - 55 years old with at least 15 years of Agilent service - as of April 30, 2016 - will only be eligible for 50 percent of the current RMA reimbursement amount upon retirement. Due to these plan amendments, we recorded a curtailment gain of $15 million in the U.S. Plans during the nine months ended July 31, 2016 . In addition, we recognized a settlement gain of $1 million related to the U.S. Supplemental Benefits Retirement Plan during the nine months ended July 31, 2016 .

WARRANTIES AND CONTINGENCIES (N

WARRANTIES AND CONTINGENCIES (Notes)	9 Months Ended
	Jul. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
WARRANTIES AND CONTINGENCIES	12. WARRANTIES AND CONTINGENCIES Warranties We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product shipments. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our condensed consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product. A summary of the standard warranty accrual activity is shown in the table below: Nine Months Ended July 31, 2016 2015 (in millions) Beginning balance as of November 1 $ 31 $ 30 Accruals for warranties including change in estimate 41 38 Settlements made during the period (36 ) (39 ) Ending balance as of July 31, $ 36 $ 29 Accruals for warranties due within one year $ 35 $ 27 Accruals for warranties due after one year 1 2 Ending balance as of July 31, $ 36 $ 29 Contingencies We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are probable and reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

SHORT-TERM DEBT (Notes)

SHORT-TERM DEBT (Notes)	9 Months Ended
	Jul. 31, 2016
Short-term Debt [Abstract]
SHORT-TERM DEBT	13. SHORT-TERM DEBT Credit Facilities On September 15, 2014 , Agilent entered into a credit agreement with a group of financial institutions which provides for a $400 million five -year unsecured credit facility that will expire on September 15, 2019 . On June 9, 2015, the commitments under the existing credit facility were increased by $300 million so that the aggregate commitments under the facility now total $700 million . As of July 31, 2016 , the company had borrowings of $235 million outstanding under the facility. We were in compliance with the covenants for the credit facility during the three and nine months ended July 31, 2016 .

LONG-TERM DEBT (Notes)

LONG-TERM DEBT (Notes)	9 Months Ended
	Jul. 31, 2016
Debt Disclosure [Abstract]
LONG-TERM DEBT	14. LONG-TERM DEBT Senior Notes The following table summarizes the company’s long-term senior notes and the related interest rate swaps: July 31, 2016 October 31, 2015 Amortized Principal Swap Total Amortized Principal Swap Total (in millions) 2017 Senior Notes $ 100 $ 1 $ 101 $ 100 $ 2 $ 102 2020 Senior Notes 499 16 515 499 19 518 2022 Senior Notes 400 — 400 399 — 399 2023 Senior Notes 598 — 598 598 — 598 Total $ 1,597 $ 17 $ 1,614 $ 1,596 $ 21 $ 1,617 All outstanding notes listed above are unsecured and rank equally in right of payment with all of Agilent’s other senior unsecured indebtedness. There have been no changes to the principal, maturity, interest rates and interest payment terms of the Agilent senior notes, detailed in the table above, in the nine months ended July 31, 2016 as compared to the senior notes described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2015 . All interest rate swap contracts have been terminated and amounts to be amortized over the remaining life of the senior notes as of July 31, 2016 and October 31, 2015 are detailed above. Other Debt As of July 31, 2016 and October 31, 2015 , we have mortgage debt, secured on buildings in Denmark, in Danish Krone equivalent of $38 million in both periods, aggregate principal, outstanding with a Danish financial institution.

STOCKHOLDERS' EQUITY (Notes)

STOCKHOLDERS' EQUITY (Notes)	9 Months Ended
	Jul. 31, 2016
Stockholders' Equity Note [Abstract]
STOCKHOLDERS EQUITY	15. STOCKHOLDERS' EQUITY Stock Repurchase Program On November 22, 2013 we announced that our board of directors had authorized a share repurchase program effective in the first quarter of fiscal year 2014, upon the conclusion of the company's previous $1 billion repurchase program. The program was designed to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs to target maintaining a weighted average share count of approximately 335 million diluted shares. During the nine months ended July 31, 2016 , we repurchased approximately 2.4 million shares for $98 million , which completed the purchases under this authorization. All such shares and related costs are held as treasury stock and accounted for using the cost method. For the nine months ended July 31, 2015 , we repurchased 6 million shares for $267 million under this plan. On May 28, 2015 we announced that our board of directors had approved a new share repurchase program (the "2015 repurchase program"). The 2015 repurchase program authorizes the purchase of up to $1.14 billion of our common stock through and including November 1, 2018. The 2015 repurchase program does not require the company to acquire a specific number of shares and may be suspended or discontinued at any time. During the three and nine months ended July 31, 2016 , upon the completion of our previous repurchase program, we repurchased approximately 2.2 million shares for $94 million and 7.3 million shares for $290 million , respectively, under this authorization. All such shares and related costs are held as treasury stock and accounted for using the cost method. As of July 31, 2016 , we had remaining authorization to repurchase up to $850 million of our common stock under this program. Cash Dividends on Shares of Common Stock During the three and nine months ended July 31, 2016 , we paid cash dividends of $0.115 per common share or $37 million and $0.345 per common share or $112 million on the company's common stock. During the three and nine months ended July 31, 2015 , we paid cash dividends of $0.100 per common share or $33 million and $0.300 per common share or $100 million on the company's common stock. The timing and amounts of any future dividends are subject to determination and approval by our board of directors. Accumulated Other Comprehensive Income (Loss) Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Three Months Ended July 31, 2016 Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of April 30, 2016 $ (100 ) $ 150 $ (344 ) $ (5 ) $ (299 ) Other comprehensive loss before reclassifications (51 ) — — (9 ) (60 ) Amounts reclassified out of accumulated other comprehensive income (loss) — (3 ) 10 2 9 Tax (expense) benefit 3 1 (2 ) 3 5 Other comprehensive income (loss) (48 ) (2 ) 8 (4 ) (46 ) As of July 31, 2016 $ (148 ) $ 148 $ (336 ) $ (9 ) $ (345 ) Nine Months Ended July 31, 2016 As of October 31, 2015 $ (189 ) $ 161 $ (365 ) $ 2 $ (391 ) Other comprehensive income (loss) before reclassifications 45 6 6 (18 ) 39 Amounts reclassified out of accumulated other comprehensive income (loss) — (26 ) 32 — 6 Tax (expense) benefit (4 ) 7 (9 ) 7 1 Other comprehensive income (loss) 41 (13 ) 29 (11 ) 46 As of July 31, 2016 $ (148 ) $ 148 $ (336 ) $ (9 ) $ (345 ) Reclassifications out of accumulated other comprehensive income (loss) for the three and nine months ended July 31, 2016 and 2015 were as follows (in millions): Details about accumulated other Amounts Reclassified Affected line item in comprehensive income (loss) components from other comprehensive income (loss) statement of operations Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 2016 2015 Unrealized gains and (losses) on derivatives $ (2 ) $ 3 $ — $ 14 Cost of products (2 ) 3 — 14 Total before income tax 1 (2 ) — (5 ) (Provision) benefit for income tax (1 ) 1 — 9 Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (10 ) (9 ) (32 ) (26 ) Prior service benefit 3 4 26 12 (7 ) (5 ) (6 ) (14 ) Total before income tax 1 1 (1 ) 2 (Provision) benefit for income tax (6 ) (4 ) (7 ) (12 ) Total net of income tax Total reclassifications for the period $ (7 ) $ (3 ) $ (7 ) $ (3 ) Amounts in parentheses indicate reductions to income and increases to other comprehensive income (loss). Reclassifications out of accumulated other comprehensive income (loss) of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost together with curtailments and settlements (see Note 11 "Retirement Plans and Post Retirement Pension Plans").

SEGMENT INFORMATION (Notes)

SEGMENT INFORMATION (Notes)	9 Months Ended
	Jul. 31, 2016
Segment Reporting [Abstract]
SEGMENT INFORMATION	16. SEGMENT INFORMATION Description of segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments. A description of our three reportable segments is as follows: Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry (“MP-AES”) instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies. Our diagnostics and genomics business is comprised of five areas of activity providing solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as active pharmaceutical ingredients ("API") in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Next, our pathology solutions business is focused on product offerings to cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry (“IHC”), in situ hybridization (“ISH”), hematoxylin and eosin (“H&E”) staining and special staining. We also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Finally, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. The majority of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements. A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate amortization and impairment of acquisition-related intangible assets, pension curtailment gain, restructuring and transformational expenses, acquisition and integration costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments. The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Three months ended July 31, 2016: Total net revenue $ 504 $ 180 $ 360 $ 1,044 Segment income from operations $ 96 $ 34 $ 82 $ 212 Three months ended July 31, 2015: Total net revenue $ 511 $ 167 $ 336 $ 1,014 Segment income from operations $ 95 $ 28 $ 76 $ 199 Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Nine months ended July 31, 2016: Total net revenue $ 1,525 $ 516 $ 1,050 $ 3,091 Segment income from operations $ 304 $ 76 $ 232 $ 612 Nine months ended July 31, 2015: Total net revenue $ 1,531 $ 484 $ 988 $ 3,003 Segment income from operations $ 277 $ 54 $ 213 $ 544 The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 2016 2015 (in millions) Total reportable segments’ income from operations $ 212 $ 199 $ 612 $ 544 Acceleration of share-based compensation related to workforce reduction — — — (2 ) Asset impairments (4 ) — (4 ) — Transformational initiatives (11 ) (12 ) (32 ) (41 ) Amortization of intangibles (37 ) (38 ) (120 ) (119 ) Acquisition and integration costs (11 ) (4 ) (28 ) (6 ) Business exit and divestiture costs (primarily our NMR business) (1 ) — (7 ) (11 ) Pension curtailment gain — — 16 — Other (2 ) (1 ) (5 ) 1 Interest income 3 2 8 6 Interest expense (17 ) (17 ) (53 ) (50 ) Other income (expense), net 2 (1 ) 6 15 Income from continuing operations before taxes, as reported $ 134 $ 128 $ 393 $ 337 The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, including deferred tax assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Assets: As of July 31, 2016 $ 1,676 $ 1,988 $ 1,057 $ 4,721 As of October 31, 2015 $ 1,539 $ 2,027 $ 1,008 $ 4,574

SUBSEQUENT EVENTS (Notes)

SUBSEQUENT EVENTS (Notes)	9 Months Ended
	Jul. 31, 2016
Subsequent Event [Line Items]
Subsequent Events [Text Block]	17. SUBSEQUENT EVENT On August 1, 2016 we completed the acquisition of substantially all of the assets of iLab Solutions LLC ("iLab"), a cloud-based solutions provider for core laboratory management . iLab Solutions' offerings enables customers to easily and accurately book time in shared facilities, to bill and invoice for projects, to manage studies, to generate reports and business intelligence, and to schedule instrument reservations across multiple projects. The purchase price was $26 million in cash . We have not yet finished allocating the purchase price to the net assets acquired. The financial results of iLab will be included within our results from the beginning of the fourth quarter of fiscal year 2016.

OVERVIEW, BASIS OF PRESENTATI26

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jul. 31, 2016
Accounting Policies [Abstract]
Overview, Segment Structure and Basis of Presentation	Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters. Basis of Presentation . We have prepared the accompanying financial data for the three and nine months ended July 31, 2016 and 2015 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2015 . In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of July 31, 2016 and October 31, 2015 , condensed consolidated statement of comprehensive income (loss) for the three and nine months ended July 31, 2016 and 2015 , condensed consolidated statement of operations for the three and nine months ended July 31, 2016 and 2015 , and condensed consolidated statement of cash flows for the nine months ended July 31, 2016 and 2015 .
Reclassification	Revision of Services and Other and Product Net Revenues and related Cost of Sales. In 2015, we revised amounts shown in our condensed consolidated statement of operations to more accurately reflect the character of items delivered to customers. Our diagnostic and genomics segment identified a stream of service revenues that had been presented as product revenue in the prior year. We have now revised prior year's presentation to show the revenue within services and other. The cost of sales associated with these newly identified service revenues has also been revised to align with the new presentation. For the three and nine months ended July 31, 2015 services and other revenue increased $11 million and $26 million and services and other cost of sales increased $7 million and $18 million with corresponding reductions in product revenue and cost of sales. These corrections to the classifications are not considered to be material to current or prior periods and had no impact to our results of operations previously reported in our condensed consolidated statement of operations.
Use of Estimates	Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, share-based compensation, retirement and post-retirement plan assumptions and accounting for income taxes.
Variable Interest Entity Disclosure	Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). The company evaluates its investments in privately held companies on an ongoing basis. We have determined that as of July 31, 2016 there were no VIE’s required to be consolidated in the company’s consolidated financial statements because we do not have a controlling financial interest in any of the VIE’s that we have invested in nor are we the primary beneficiary. We account for these investments under either the equity or cost method, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. As of July 31, 2016 , the carrying value of our investments in VIE’s was $101 million with a maximum exposure of $108 million which includes our loans to our investments. The investments are included on the long term investments line of the condensed consolidated balance sheet. During the nine months ended July 31, 2016 , Agilent made a preferred stock investment in Lasergen for $80 million . Agilent’s initial ownership stake was 48 percent and we have also joined the board of Lasergen and signed a collaboration agreement. We have the option to acquire all of the remaining shares of Lasergen until March 2, 2018, for additional consideration of $105 million . Lasergen is a VIE, however, we do not consolidate the entity in our financial statements because we do not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance. Because of the nature of the preferred stock of Lasergen that we own, we account for this investment under the cost method. As of July 31, 2016 , both the carrying value and maximum exposure of the Lasergen investment was $80 million . The maximum exposure is equal to the carrying value because we do not have future funding commitments.
Fair Value of Financial Instruments	Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments is determined using quoted market prices for those securities when available. For those long-term equity investments accounted for under the cost or equity method, their carrying value approximates their estimated fair value. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. The fair value of our long-term debt, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately $102 million and $30 million as of July 31, 2016 and October 31, 2015 , respectively. The change in the excess of fair value over carrying value in the nine months ended July 31, 2016 is due to fluctuations in market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 9, "Fair Value Measurements" for additional information on the fair value of financial instruments.
Goodwill and Purchased Intangible Assets	Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e. greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required. The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers. If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. In fiscal year 2015, we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a quantitative test for goodwill impairment of the three reporting units, as of September 30, 2015. Based on the results of our testing, the fair value of these reporting units are greater than their respective carrying values. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the three and nine months ended July 31, 2016 and 2015 . Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years . In-process research and development ("IPR&D") is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's condensed consolidated statement of operations in the period it is abandoned. Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e. greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2015. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of these indefinite-lived intangible assets is greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets is indicated. During the three and nine months ended July 31, 2016 , we recorded an impairment of $4 million due to the announced cancellation of a certain IPR&D project. There were no impairments in the three and nine months ended July 31, 2015 .

REVISION OF PRIOR PERIOD FINA27

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Tables)	9 Months Ended
	Jul. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	For the three and nine months ended July 31, 2016 , we are presenting comparative fiscal 2015 quarterly information. The fiscal 2015 results for the three and nine months ended July 31, 2015 have been revised to reflect the quarterly impact of the out of period adjustments described above. For the three months ended July 31, 2015 the following out of period adjustments were included in the as-reported column in the revision adjustment table and have been removed in the adjustments column: $8 million of tax expense related to the correction of the U.S. deferred tax liability for unremitted earnings of foreign subsidiaries. In addition to the aforementioned, for the nine months ended July 31, 2015 , the following out of period adjustments were included in the as-reported column in the revision adjustment table and have been removed in the adjustments column: $4 million of tax expense related to the increase of foreign deferred tax liabilities for a prior year, $13 million of tax benefit from the reduction in deferred tax liabilities due to tax rate changes in Denmark occurring in a prior year and $4 million of tax expense attributable to an error discovered on a prior year U.S. tax return. Three Months Ended July 31, 2015 As Reported Adjustments As Revised (in millions, except per share data) Income from continuing operations before taxes $ 128 $ 128 Provision for income taxes 23 (8 ) 15 Income from continuing operations 105 113 Loss from discontinued operations, net of tax benefit of $0 million (2 ) (2 ) Net Income $ 103 $ 8 $ 111 Net income per share - basic Income from continuing operations $ 0.32 $ 0.34 Loss from discontinued operations (0.01 ) (0.01 ) Net income per share - basic $ 0.31 $ 0.33 Net income per share - diluted Income from continuing operations $ 0.31 $ 0.34 Loss from discontinued operations — (0.01 ) Net income per share - diluted $ 0.31 $ 0.33 Total comprehensive income $ 41 $ 8 $ 49 Nine Months Ended July 31, 2015 As Reported Adjustments As Revised (in millions, except per share data) Income from continuing operations before taxes $ 337 $ 337 Provision for income taxes 42 (3 ) 39 Income from continuing operations 295 298 Loss from discontinued operations, net of tax benefit of $(2) (37 ) (37 ) Net Income $ 258 $ 3 $ 261 Net income per share - basic Income from continuing operations $ 0.88 $ 0.89 Loss from discontinued operations (0.11 ) (0.11 ) Net income per share - basic $ 0.77 $ 0.78 Net income per share - diluted Income from continuing operations $ 0.88 $ 0.89 Loss from discontinued operations (0.11 ) (0.11 ) Net income per share - diluted $ 0.77 $ 0.78 Total comprehensive loss $ (72 ) $ 3 $ (69 ) The adjustments resulted in the following revisions to our condensed consolidated statement of cash flow. Nine Months Ended July 31, 2015 As Reported Adjustments As Revised (1) (in millions) Net income $ 258 $ 3 $ 261 Deferred taxes $ (15 ) $ (1 ) $ (16 ) Changes in assets and liabilities: Other assets and liabilities $ (162 ) $ (2 ) $ (164 ) Net cash provided by operating activities $ 254 $ — $ 254

NEW ACCOUNTING PRONOUNCEMENTS28

NEW ACCOUNTING PRONOUNCEMENTS (Tables)	9 Months Ended
	Jul. 31, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Schedule of the impact of the early adoption of new accounting pronouncement on previously reported financial statements	The adoption of the new guidance did not have a significant impact on the calculation of diluted weighted average shares. The impact of the adoption on our previously reported quarterly results for fiscal year 2016 follows: Three Months Ended January 31, 2016 Six Months Ended April 30, 2016 As Reported As Adjusted As As (in millions, except per share amounts) Condensed Consolidated Statement of Operations: Provision for income taxes $ 19 $ 21 $ 45 $ 47 Net income $ 123 $ 121 $ 214 $ 212 Net income per share - Basic $ 0.37 $ 0.37 $ 0.65 $ 0.65 Net income per share - Diluted $ 0.37 $ 0.36 $ 0.65 $ 0.64 Weighted average shares used in computing net income per share - Diluted 332 332 330 330 We elected to apply the presentation requirements for cash flows related to excess tax benefits and employee taxes paid for withheld shares retrospectively to all periods presented which resulted in an increase to both net cash from operations and net cash used in financing of $1 million and $6 million for the three and nine months ended July 31, 2016, respectively. The presentation requirements for cash flows also impacted our previously reported quarterly condensed consolidated statement of cash flows for fiscal years 2016 and 2015 as follows: Three Months Ended Six Months Ended As As Adjusted As As Adjusted (in millions) Condensed Consolidated Statement of Cash Flows: Net cash provided by operating activities $ 104 $ 111 $ 360 $ 365 Net cash used in financing activities $ (132 ) $ (139 ) $ (102 ) $ (107 ) Three Months Ended January 31, 2015 Six Months Ended April 30, 2015 Nine Months Ended July 31, 2015 As As Adjusted As As Adjusted As (1) As Adjusted (in millions) Condensed Consolidated Statement of Cash Flows: Net cash provided by (used in) operating activities $ (20 ) $ (9 ) $ 163 $ 175 $ 254 $ 271 Net cash used in financing activities $ (828 ) $ (839 ) $ (929 ) $ (941 ) $ (1,039 ) $ (1,056 ) (1) See Note 2, "Revision of Prior Period Financial Statements" for additional information. January 31, 2016 April 30, 2016 As As As As (in millions) Condensed Consolidated Balance Sheet: Other assets $ 242 $ 353 $ 339 $ 436 Other accrued liabilities $ 169 $ 168 $ 188 $ 187 Other long-term liabilities $ 412 $ 329 $ 446 $ 347 Additional paid-in-capital $ 9,085 $ 9,087 $ 9,103 $ 9,107 Retained earnings $ 5,666 $ 5,859 $ 5,720 $ 5,913

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	9 Months Ended
	Jul. 31, 2016
Share-based Compensation [Abstract]
Allocated Share-based compensation expense disclosure	The impact on our results for share-based compensation was as follows: Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 2016 2015 (in millions) Cost of products and services $ 2 $ 2 $ 11 $ 9 Research and development 1 1 4 4 Selling, general and administrative 8 7 33 31 Total share-based compensation expense $ 11 $ 10 $ 48 $ 44
Assumptions used to estimate fair value for stock options and LTPP	The following assumptions were used to estimate the fair value of the options and LTPP grants. Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 2016 2015 Stock Option Plans: Weighted average risk-free interest rate — — — 1.7 % Dividend yield — — — 1 % Weighted average volatility — — — 28 % Expected life — — — 5.5yrs LTPP: Volatility of Agilent shares 24% 25% 24 % 25 % Volatility of selected peer-company shares 14%-50% 12%-57% 14%-50% 12%-57% Price-wise correlation with selected peers 35% 37% 35 % 37 %

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	9 Months Ended
	Jul. 31, 2016
Earnings Per Share [Abstract]
Reconciliation of the numerators and denominators of the basic and diluted net income per share	The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below: Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 (As Revised) 2016 2015 (As Revised) (in millions) Numerator: Income from continuing operations $ 124 $ 113 $ 336 $ 298 Loss from discontinued operations — (2 ) — (37 ) Net income $ 124 $ 111 $ 336 $ 261 Denominator: Basic weighted-average shares 325 332 326 334 Potential common shares— stock options and other employee stock plans 3 2 3 2 Diluted weighted-average shares 328 334 329 336

INVENTORY (Tables)

INVENTORY (Tables)	9 Months Ended
	Jul. 31, 2016
Inventory, Net [Abstract]
INVENTORY	7. INVENTORY July 31, October 31, (in millions) Finished goods $ 351 $ 362 Purchased parts and fabricated assemblies 192 179 Inventory $ 543 $ 541

GOODWILL AND OTHER INTANGIBLE32

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Jul. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill balances and movements for each reportable segments during the period	The following table presents goodwill balances and the movements for each of our reportable segments during the nine months ended July 31, 2016 : Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2015 $ 650 $ 1,234 $ 482 $ 2,366 Foreign currency translation impact 5 14 3 22 Goodwill arising from acquisitions 137 — — 137 Goodwill as of July 31, 2016: $ 792 $ 1,248 $ 485 $ 2,525
Components of other intangibles during the period	The components of other intangibles as of July 31, 2016 and October 31, 2015 are shown in the table below: Purchased Other Intangible Assets Gross Carrying Amount Accumulated Amortization Net Book Value (in millions) As of October 31, 2015: Purchased technology $ 746 $ 476 $ 270 Trademark/Tradename 141 50 91 Customer relationships 230 168 62 Total amortizable intangible assets 1,117 694 423 In-Process R&D 22 — 22 Total $ 1,139 $ 694 $ 445 As of July 31, 2016: Purchased technology $ 830 $ 553 $ 277 Backlog 1 1 — Trademark/Tradename 151 59 92 Customer relationships 263 208 55 Total amortizable intangible assets 1,245 821 424 In-Process R&D 18 — 18 Total $ 1,263 $ 821 $ 442
Schedule of estimated future amortization expense of finite-lived intangible assets	Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2016 and for each of the five succeeding fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) Remainder of 2016 $ 32 2017 $ 112 2018 $ 82 2019 $ 58 2020 $ 48 2021 $ 35 Thereafter $ 57

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Jul. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Assets And Liabilities Measured On Recurring Basis	Financial assets and liabilities measured at fair value on a recurring basis as of July 31, 2016 were as follows: Fair Value Measurement at July 31, 2016 Using July 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,398 $ 1,398 $ — $ — Derivative instruments (foreign exchange contracts) 5 — 5 — Long-term Trading securities 31 31 — — Total assets measured at fair value $ 1,434 $ 1,429 $ 5 $ — Liabilities: Short-term Derivative instruments (foreign exchange and interest rate swap contracts) $ 22 $ — $ 22 $ — Long-term Deferred compensation liability 31 — 31 — Total liabilities measured at fair value $ 53 $ — $ 53 $ — Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2015 were as follows: Fair Value Measurement at October 31, 2015 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,411 $ 1,411 $ — $ — Derivative instruments (foreign exchange contracts) 4 — 4 — Long-term Trading securities 35 35 — — Total assets measured at fair value $ 1,450 $ 1,446 $ 4 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Long-term Deferred compensation liability 35 — 35 — Total liabilities measured at fair value $ 40 $ — $ 40 $ —

DERIVATIVES (Tables)

DERIVATIVES (Tables)	9 Months Ended
	Jul. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Aggregated notional amounts by currency and designation	The aggregated notional amounts by currency and designation as of July 31, 2016 were as follows: Derivatives Designated as Cash Flow Hedges Derivatives Not Designated as Hedging Instruments Forward Contracts USD Forward Contracts USD Forward Contracts DKK Currency Buy/(Sell) Buy/(Sell) Buy/(Sell) (in millions) Euro $ (46 ) $ 105 $ (64 ) British Pound (34 ) — (4 ) Canadian Dollar (26 ) — (2 ) Australian Dollar 4 12 (4 ) Malaysian Ringgit — (2 ) — Japanese Yen (75 ) 21 (3 ) American Dollar — — 50 Other (6 ) 31 (15 ) Totals $ (183 ) $ 167 $ (42 )
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet	Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of July 31, 2016 and October 31, 2015 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location July 31, October 31, Balance Sheet Location July 31, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange forward contracts $ 3 $ 2 $ 7 $ 1 Interest rate swap contracts — — 14 — Other current assets $ 3 $ 2 Other accrued liabilities $ 21 $ 1 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 2 $ 2 Other accrued liabilities $ 1 $ 4 Total derivatives $ 5 $ 4 $ 22 $ 5
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations	The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 2016 2015 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive income (loss) $ 2 $ 3 $ (4 ) $ 11 Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales $ (2 ) $ 3 $ — $ 14 Interest rate swap contracts: Loss recognized in accumulated other comprehensive income (loss) $ (11 ) $ — $ (14 ) $ — Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense) $ (2 ) $ (3 ) $ 3 $ (20 )

RETIREMENT PLANS AND POST RET35

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)	9 Months Ended
	Jul. 31, 2016
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Schedule of net pension and post-retirement benefit costs	Components of net periodic costs. For the three and nine months ended July 31, 2016 and 2015 , our net pension and post retirement benefit costs were comprised of the following: Pensions U.S. Plans Non-U.S. Plans U.S. Post Retirement Benefit Plans Three Months Ended July 31, 2016 2015 2016 2015 2016 2015 (in millions) Service cost—benefits earned during the period $ — $ 6 $ 5 $ 4 $ — $ 1 Interest cost on benefit obligation 4 3 4 6 1 1 Expected return on plan assets (6 ) (7 ) (11 ) (10 ) (2 ) (2 ) Amortization: Actuarial losses — 2 7 6 3 1 Prior service cost — (1 ) — — (3 ) (3 ) Total net plan costs $ (2 ) $ 3 $ 5 $ 6 $ (1 ) $ (2 ) Curtailments and settlements $ — Pensions U.S. Plans Non-U.S. U.S. Post Retirement Nine Months Ended July 31, 2016 2015 2016 2015 2016 2015 (in millions) Service cost—benefits earned during the period $ 12 $ 18 $ 14 $ 12 $ — $ 3 Interest cost on benefit obligation 11 10 12 18 3 3 Expected return on plan assets (18 ) (21 ) (33 ) (31 ) (5 ) (6 ) Amortization: Actuarial losses 2 4 21 19 8 3 Prior service cost (2 ) (3 ) — — (8 ) (9 ) Total net plan costs $ 5 $ 8 $ 14 $ 18 $ (2 ) $ (6 ) Curtailment and settlements $ (16 )

WARRANTIES AND CONTINGENCIES (T

WARRANTIES AND CONTINGENCIES (Tables)	9 Months Ended
	Jul. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Standard warranty	A summary of the standard warranty accrual activity is shown in the table below: Nine Months Ended July 31, 2016 2015 (in millions) Beginning balance as of November 1 $ 31 $ 30 Accruals for warranties including change in estimate 41 38 Settlements made during the period (36 ) (39 ) Ending balance as of July 31, $ 36 $ 29 Accruals for warranties due within one year $ 35 $ 27 Accruals for warranties due after one year 1 2 Ending balance as of July 31, $ 36 $ 29

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	9 Months Ended
	Jul. 31, 2016
Debt Disclosure [Abstract]
Schedule of Senior Notes and Related Interest Rate Swaps	The following table summarizes the company’s long-term senior notes and the related interest rate swaps: July 31, 2016 October 31, 2015 Amortized Principal Swap Total Amortized Principal Swap Total (in millions) 2017 Senior Notes $ 100 $ 1 $ 101 $ 100 $ 2 $ 102 2020 Senior Notes 499 16 515 499 19 518 2022 Senior Notes 400 — 400 399 — 399 2023 Senior Notes 598 — 598 598 — 598 Total $ 1,597 $ 17 $ 1,614 $ 1,596 $ 21 $ 1,617

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Jul. 31, 2016
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Three Months Ended July 31, 2016 Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of April 30, 2016 $ (100 ) $ 150 $ (344 ) $ (5 ) $ (299 ) Other comprehensive loss before reclassifications (51 ) — — (9 ) (60 ) Amounts reclassified out of accumulated other comprehensive income (loss) — (3 ) 10 2 9 Tax (expense) benefit 3 1 (2 ) 3 5 Other comprehensive income (loss) (48 ) (2 ) 8 (4 ) (46 ) As of July 31, 2016 $ (148 ) $ 148 $ (336 ) $ (9 ) $ (345 ) Nine Months Ended July 31, 2016 As of October 31, 2015 $ (189 ) $ 161 $ (365 ) $ 2 $ (391 ) Other comprehensive income (loss) before reclassifications 45 6 6 (18 ) 39 Amounts reclassified out of accumulated other comprehensive income (loss) — (26 ) 32 — 6 Tax (expense) benefit (4 ) 7 (9 ) 7 1 Other comprehensive income (loss) 41 (13 ) 29 (11 ) 46 As of July 31, 2016 $ (148 ) $ 148 $ (336 ) $ (9 ) $ (345 )
Reclassification out of Accumulated Other Comprehensive Income	Reclassifications out of accumulated other comprehensive income (loss) for the three and nine months ended July 31, 2016 and 2015 were as follows (in millions): Details about accumulated other Amounts Reclassified Affected line item in comprehensive income (loss) components from other comprehensive income (loss) statement of operations Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 2016 2015 Unrealized gains and (losses) on derivatives $ (2 ) $ 3 $ — $ 14 Cost of products (2 ) 3 — 14 Total before income tax 1 (2 ) — (5 ) (Provision) benefit for income tax (1 ) 1 — 9 Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (10 ) (9 ) (32 ) (26 ) Prior service benefit 3 4 26 12 (7 ) (5 ) (6 ) (14 ) Total before income tax 1 1 (1 ) 2 (Provision) benefit for income tax (6 ) (4 ) (7 ) (12 ) Total net of income tax Total reclassifications for the period $ (7 ) $ (3 ) $ (7 ) $ (3 )

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
	Jul. 31, 2016
Segment Reporting [Abstract]
Segment Profitability and Segment Assets	The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Three months ended July 31, 2016: Total net revenue $ 504 $ 180 $ 360 $ 1,044 Segment income from operations $ 96 $ 34 $ 82 $ 212 Three months ended July 31, 2015: Total net revenue $ 511 $ 167 $ 336 $ 1,014 Segment income from operations $ 95 $ 28 $ 76 $ 199 Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Nine months ended July 31, 2016: Total net revenue $ 1,525 $ 516 $ 1,050 $ 3,091 Segment income from operations $ 304 $ 76 $ 232 $ 612 Nine months ended July 31, 2015: Total net revenue $ 1,531 $ 484 $ 988 $ 3,003 Segment income from operations $ 277 $ 54 $ 213 $ 544 The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, including deferred tax assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Assets: As of July 31, 2016 $ 1,676 $ 1,988 $ 1,057 $ 4,721 As of October 31, 2015 $ 1,539 $ 2,027 $ 1,008 $ 4,574
Reconciliation of segment results to total enterprise results	The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: Three Months Ended Nine Months Ended July 31, July 31, 2016 2015 2016 2015 (in millions) Total reportable segments’ income from operations $ 212 $ 199 $ 612 $ 544 Acceleration of share-based compensation related to workforce reduction — — — (2 ) Asset impairments (4 ) — (4 ) — Transformational initiatives (11 ) (12 ) (32 ) (41 ) Amortization of intangibles (37 ) (38 ) (120 ) (119 ) Acquisition and integration costs (11 ) (4 ) (28 ) (6 ) Business exit and divestiture costs (primarily our NMR business) (1 ) — (7 ) (11 ) Pension curtailment gain — — 16 — Other (2 ) (1 ) (5 ) 1 Interest income 3 2 8 6 Interest expense (17 ) (17 ) (53 ) (50 ) Other income (expense), net 2 (1 ) 6 15 Income from continuing operations before taxes, as reported $ 134 $ 128 $ 393 $ 337

OVERVIEW, BASIS OF PRESENTATI40

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	Mar. 02, 2016	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015	Oct. 31, 2015
Variable Interest Entity Disclosures
Carrying Value of Investments in VIE's		$ 101		$ 101
Maximum Exposure of investments in VIE's		108		108
Investment in Lasergen	$ 80
Percentage of Ownership in Lasergen	48.00%
Call option amount to acquire remaining shares of business	$ 105
Fair Value of Financial Instruments
Fair value of long term debt in excess of carrying value		102		102		$ 30
Goodwill and Purchased Intangible Assets
Impairment of goodwill		0	$ 0	0
Impairment of IPR&D		$ 4	0	$ 4	$ 0
Minimum
Finite-Lived Intangible Assets
Purchased intangible assets useful life		6 months
Maximum
Finite-Lived Intangible Assets
Purchased intangible assets useful life		15 years
Services and other revenue
Income Statement
Prior period reclassification adjustment			11		26
Services and other cost of sales
Income Statement
Prior period reclassification adjustment			$ 7		$ 18

REVISION OF PRIOR PERIOD FINA41

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Income Statement
Income from continuing operations before taxes	$ 134	$ 128	$ 393	$ 337
Provision for income taxes	10	15	57	39
Income from continuing operations	124	113	336	298
Loss from discontinued operations, net of tax expense benefit of $2	0	(2)	0	(37)
Net income	$ 124	$ 111	$ 336	$ 261
Net income per share - basic
Income from continuing operations	$ 0.38	$ 0.34	$ 1.03	$ 0.89
Loss from discontinued operations	0	(0.01)	0	(0.11)
Net income per share - basic	0.38	0.33	1.03	0.78
Net income per share - diluted
Income from continuing operations	0.38	0.34	1.02	0.89
Loss from discontinued operations	0	(0.01)	0	(0.11)
Net income per share - diluted	$ 0.38	$ 0.33	$ 1.02	$ 0.78
Statement of Comprehensive Income
Total comprehensive income (loss)	$ 78	$ 49	$ 382	$ (69)
Statement of Cash Flows
Deferred taxes			34	(16)
Other assets and liabilities			(47)	(152)
Net cash provided by operating activities			$ 559	271
As Previously Reported
Income Statement
Income from continuing operations before taxes		128		337
Provision for income taxes		23		42
Income from continuing operations		105		295
Loss from discontinued operations, net of tax expense benefit of $2		(2)		(37)
Net income		$ 103		$ 258
Net income per share - basic
Income from continuing operations		$ 0.32		$ 0.88
Loss from discontinued operations		(0.01)		(0.11)
Net income per share - basic		0.31		0.77
Net income per share - diluted
Income from continuing operations		0.31		0.88
Loss from discontinued operations		0		(0.11)
Net income per share - diluted		$ 0.31		$ 0.77
Statement of Comprehensive Income
Total comprehensive income (loss)		$ 41		$ (72)
Statement of Cash Flows
Deferred taxes				(15)
Other assets and liabilities				(162)
Net cash provided by operating activities				254
As Revised
Income Statement
Income from continuing operations before taxes		128		337
Provision for income taxes		15		39
Income from continuing operations		113		298
Loss from discontinued operations, net of tax expense benefit of $2		(2)		(37)
Net income		$ 111		$ 261
Net income per share - basic
Income from continuing operations		$ 0.34		$ 0.89
Loss from discontinued operations		(0.01)		(0.11)
Net income per share - basic		0.33		0.78
Net income per share - diluted
Income from continuing operations		0.34		0.89
Loss from discontinued operations		(0.01)		(0.11)
Net income per share - diluted		$ 0.33		$ 0.78
Statement of Comprehensive Income
Total comprehensive income (loss)		$ 49		$ (69)
Statement of Cash Flows
Deferred taxes				(16)
Other assets and liabilities				(164)
Net cash provided by operating activities				254
Revision Adjustment
Income Statement
Prior period tax adjustments		$ 8		3
Net income per share - diluted
Deferred income tax adjustment				(1)
Statement of Cash Flows
Increase (decrease) in Income taxes payable				(2)
Impact of tax adjustment to cash from operating activities				0
Foreign deferred tax liabilities [Member] [Member] | Revision Adjustment
Net income per share - diluted
Tax expense (benefit)				4
Foreign tax rate change [Member] | Revision Adjustment
Net income per share - diluted
Deferred income tax adjustment				13
Due to Error in prior year tax return [Member] | Revision Adjustment
Net income per share - diluted
Tax expense (benefit)				$ 4

NEW ACCOUNTING PRONOUNCEMENTS -

NEW ACCOUNTING PRONOUNCEMENTS - Statement of Operations (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended			6 Months Ended	9 Months Ended
	Jul. 31, 2016	Jan. 31, 2016	Jul. 31, 2015	Apr. 30, 2016	Jul. 31, 2016	Jul. 31, 2015
Provision for income taxes	$ 10		$ 15		$ 57	$ 39
Net income	$ 124		$ 111		$ 336	$ 261
Net income per share - Basic	$ 0.38		$ 0.33		$ 1.03	$ 0.78
Net income per share - Diluted	$ 0.38		$ 0.33		$ 1.02	$ 0.78
Weighted average shares used in computing net income per share - Diluted	328		334		329	336
As Previously Reported
Provision for income taxes		$ 19		$ 45
Net income		$ 123		$ 214
Net income per share - Basic		$ 0.37		$ 0.65
Net income per share - Diluted		$ 0.37		$ 0.65
Weighted average shares used in computing net income per share - Diluted		332		330
As Adjusted
Provision for income taxes		$ 21		$ 47
Net income		$ 121		$ 212
Net income per share - Basic		$ 0.37		$ 0.65
Net income per share - Diluted		$ 0.36		$ 0.64
Weighted average shares used in computing net income per share - Diluted		332		330

NEW ACCOUNTING PRONOUNCEMENTS43

NEW ACCOUNTING PRONOUNCEMENTS - Statement of Cash Flows (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2016	Apr. 30, 2015	Jul. 31, 2016	Jul. 31, 2015
Net cash provided by (used in) operating activities					$ 559	$ 271
Net cash used in financing activities					$ (212)	(1,056)
As Previously Reported
Net cash provided by (used in) operating activities	$ 104	$ (20)	$ 360	$ 163
Net cash used in financing activities	(132)	(828)	(102)	(929)
As Adjusted
Net cash provided by (used in) operating activities	111	(9)	365	175		271
Net cash used in financing activities	$ (139)	$ (839)	$ (107)	$ (941)		(1,056)
As Revised
Net cash provided by (used in) operating activities						254
Net cash used in financing activities						$ (1,039)

NEW ACCOUNTING PRONOUNCEMENTS44

NEW ACCOUNTING PRONOUNCEMENTS - Balance Sheet (Details) - USD ($) $ in Millions	Jul. 31, 2016	Apr. 30, 2016	Jan. 31, 2016	Nov. 01, 2015	Oct. 31, 2015
Cumulative effect adjustment to retained earnings				$ 195
Other assets	$ 459				$ 292
Other accrued liabilities	167				218
Other long-term liabilities	356				414
Additional paid-in-capital	9,144				9,045
Retained earnings	$ 6,000				$ 5,581
As Previously Reported
Other assets		$ 339	$ 242
Other accrued liabilities		188	169
Other long-term liabilities		446	412
Additional paid-in-capital		9,103	9,085
Retained earnings		5,720	5,666
As Adjusted
Other assets		436	353
Other accrued liabilities		187	168
Other long-term liabilities		347	329
Additional paid-in-capital		9,107	9,087
Retained earnings		$ 5,913	$ 5,859
retained earnings due to minimum statutory requirements [Member]
Cumulative effect adjustment to retained earnings				$ 0

NEW ACCOUNTING PRONOUNCEMENTS N

NEW ACCOUNTING PRONOUNCEMENTS NEW ACCOUNTING PRONOUNCEMENTS - Textuals (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Jul. 31, 2016	Jan. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015	Apr. 30, 2016	Oct. 31, 2015
Provision for income taxes	$ 10		$ 15	$ 57	$ 39
Other assets	459			459			$ 292
Additional paid-in-capital	9,144			9,144			9,045
Other accrued liabilities	167			167			218
Other long-term liabilities	356			356			$ 414
Net cash provided by operating activities				559	271
Net cash used in financing activities				(212)	$ (1,056)
Adjustments for New Accounting Principle, Early Adoption [Member]
Provision for income taxes		$ 2
Other assets						$ 97
Additional paid-in-capital						4
Other accrued liabilities						(1)
Other long-term liabilities						$ (99)
Net cash provided by operating activities	1			6
Net cash used in financing activities	$ (1)			$ (6)

SHARE-BASED COMPENSATION Alloca

SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015	Oct. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 11	$ 10	$ 48	$ 44
Inventory
Share-based Compensation, Allocation and Classification in Financial Statements
Capitalized share-based compensation			0		$ 0
Cost of Products and Services
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	2	2	11	9
Research and Development Expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	1	1	4	4
Selling, General and Administrative Expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 8	$ 7	$ 33	$ 31

SHARE-BASED COMPENSATION Fair V

SHARE-BASED COMPENSATION Fair Value Assumptions (Details) shares in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016yrshares	Jul. 31, 2015yr	Jul. 31, 2016yrshares	Jul. 31, 2015yr
Share-based Compensation Arrangement by Share-based Payment Award
Stock options granted | shares	0		0
ESPP plan purchase price (in hundredths)	85.00%	85.00%
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average risk-free interest rate (in hundredths)	0.00%	0.00%	0.00%	1.70%
Dividend yield	0.00%	0.00%	0.00%	1.00%
Weighted average volatility (in hundredths)	0.00%	0.00%	0.00%	28.00%
Expected life (in years)				5 years 6 months
Number of years of peer groups historical stock price volatility used to determine volatility		5.5		5.5
LTPP
Share-based Compensation Arrangement by Share-based Payment Award
Volatility of Agilent shares (in hundredths)	24.00%	25.00%	24.00%	25.00%
Volatility of selected peer-company shares minimum (in hundredths)	14.00%	12.00%	14.00%	12.00%
Volatility of selected peer-company shares maximum (in hundredths)	50.00%	57.00%	50.00%	57.00%
Price-wise correlation with selected peers (in hundredths)	35.00%	37.00%	35.00%	37.00%
Number of years of peer groups historical stock price volatility used to determine volatility	3	3	3	3

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015	Jan. 31, 2015
Income Tax Disclosure
Effective Income Tax Rate, Percent	7.50%	11.70%	14.50%	11.60%
Provision for income taxes	$ 10	$ 15	$ 57	$ 39
Net Discrete Tax Expense (Benefit)	(6)	1	(9)	(15)
Income Taxes Paid			9
Prepaid Taxes					$ 3
Internal Revenue Service
Incremental taxes					$ 12
Internal Revenue Service (IRS)
Internal Revenue Service
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions				119
Tax liability on foreign earnings distributions				99
Deferred tax liability for unremitted foreign earnings [Member]
Income Tax Disclosure
Discrete Tax Expense (Benefit)	(11)
U.S. Research & Development Tax Credit Extension
Income Tax Disclosure
Discrete Tax Expense (Benefit)			(5)	(6)
Pension Curtailment
Income Tax Disclosure
Discrete Tax Expense (Benefit)			6
Return To Provision Adjustment
Income Tax Disclosure
Discrete Tax Expense (Benefit)			5
Interest Accruals for uncertain tax positions [Member]
Income Tax Disclosure
Discrete Tax Expense (Benefit)		1
Realization of tax credits [Member]
Income Tax Disclosure
Discrete Tax Expense (Benefit)			(8)
Other Discrete Items
Income Tax Disclosure
Discrete Tax Expense (Benefit)	5		4	$ 6
De-registration of certain foreign branches [Member]
Income Tax Disclosure
Discrete Tax Expense (Benefit)		$ (16)
share-based awards [Member]
Income Tax Disclosure
Provision for income taxes	$ (3)		$ (1)

NET INCOME PER SHARE (Details)

NET INCOME PER SHARE (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Numerator:
Income from continuing operations	$ 124	$ 113	$ 336	$ 298
Loss from discontinued operations	0	(2)	0	(37)
Net income	$ 124	$ 111	$ 336	$ 261
Denominators:
Basic weighted-average shares (in shares)	325,000,000	332,000,000	326,000,000	334,000,000
Potential common shares - stock options and other employee stock plans (in shares)	3,000,000	2,000,000	3,000,000	2,000,000
Diluted weighted average shares (in shares)	328,000,000	334,000,000	329,000,000	336,000,000
Options with exercise price greater than average market price
Antidilutive Securities Excluded from EPS Computation
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0	1,200,000	1,100,000	856,900
Stock Options, LTPP and restricted stock combined exercise price, unamortized fair value, excess tax benefits or shortfalls greater than average market price
Antidilutive Securities Excluded from EPS Computation
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0	80,900	306,100	487,100

INVENTORY (Details)

INVENTORY (Details) - USD ($) $ in Millions	Jul. 31, 2016	Oct. 31, 2015
Inventory, Net [Abstract]
Finished goods	$ 351	$ 362
Purchased parts and fabricated assemblies	192	179
Inventory	$ 543	$ 541

GOODWILL AND OTHER INTANGIBLE51

GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details) $ in Millions	9 Months Ended
	Jul. 31, 2016USD ($)
Goodwill Roll Forward
Goodwill beginning balance	$ 2,366
Foreign currency translation impact	22
Goodwill arising from acquisitions	137
Goodwill ending balance	2,525
Life Sciences and Applied Markets
Goodwill Roll Forward
Goodwill beginning balance	650
Foreign currency translation impact	5
Goodwill arising from acquisitions	137
Goodwill ending balance	792
Diagnostics and Genomics
Goodwill Roll Forward
Goodwill beginning balance	1,234
Foreign currency translation impact	14
Goodwill arising from acquisitions	0
Goodwill ending balance	1,248
Agilent CrossLab
Goodwill Roll Forward
Goodwill beginning balance	482
Foreign currency translation impact	3
Goodwill arising from acquisitions	0
Goodwill ending balance	$ 485

GOODWILL AND OTHER INTANGIBLE52

GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details) - USD ($) $ in Millions	Jul. 31, 2016	Oct. 31, 2015
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	$ 1,263	$ 1,139
Accumulated Amortization and Impairments	821	694
Net Book Value	442	445
Purchased Technology
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	830	746
Accumulated Amortization and Impairments	553	476
Net Book Value	277	270
Backlog
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	1
Accumulated Amortization and Impairments	1
Net Book Value	0
Trademark/Tradenames
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	151	141
Accumulated Amortization and Impairments	59	50
Net Book Value	92	91
Customer Relationships
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	263	230
Accumulated Amortization and Impairments	208	168
Net Book Value	55	62
Total amortizable intangible assets
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	1,245	1,117
Accumulated Amortization and Impairments	821	694
Net Book Value	424	423
In-Process R&D
Indefinite-Lived Intangible Assets (Excluding Goodwill)
In-Process R&D	$ 18	$ 22

GOODWILL AND OTHER INTANGIBLE53

GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) - USD ($) $ in Millions	Nov. 01, 2015	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Finite-Lived Intangible Assets
Additions to goodwill				$ 137
Addition to other intangible assets				118	$ 0
Foreign exchange translation impact				3
Impairment of IPR&D		$ 4	$ 0	4	0
Amortization of intangible assets during the period		$ 37	$ 38	$ 120	$ 119
Seahorse Bioscience
Acquisition
Purchase price of acquisition	$ 242

GOODWILL AND OTHER INTANGIBLE54

GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details) $ in Millions	Jul. 31, 2016USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2016	$ 32
2,017	112
2,018	82
2,019	58
2,020	48
2,021	35
Thereafter	$ 57

FAIR VALUE MEASUREMENTS, Fair v

FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Jul. 31, 2016	Oct. 31, 2015
Assets Short - term
Cash equivalents (money market funds)	$ 1,398	$ 1,411
Derivative instruments (foreign exchange contracts)	5	4
Assets, Long-term
Trading securities	31	35
Total assets measured at fair value	1,434	1,450
Liabilities, Short-term
Derivative instruments (foreign exchange and interest rate swap contracts)	22	5
Liabilities Long-term
Deferred compensation liability	31	35
Total liabilities measured at fair value	53	40
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets Short - term
Cash equivalents (money market funds)	1,398	1,411
Derivative instruments (foreign exchange contracts)	0	0
Assets, Long-term
Trading securities	31	35
Total assets measured at fair value	1,429	1,446
Liabilities, Short-term
Derivative instruments (foreign exchange and interest rate swap contracts)	0	0
Liabilities Long-term
Deferred compensation liability	0	0
Total liabilities measured at fair value	0	0
Significant Other Observable Inputs (Level 2)
Assets Short - term
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	5	4
Assets, Long-term
Trading securities	0	0
Total assets measured at fair value	5	4
Liabilities, Short-term
Derivative instruments (foreign exchange and interest rate swap contracts)	22	5
Liabilities Long-term
Deferred compensation liability	31	35
Total liabilities measured at fair value	53	40
Significant Unobservable Inputs (Level 3)
Assets Short - term
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	0	0
Assets, Long-term
Trading securities	0	0
Total assets measured at fair value	0	0
Liabilities, Short-term
Derivative instruments (foreign exchange and interest rate swap contracts)	0	0
Liabilities Long-term
Deferred compensation liability	0	0
Total liabilities measured at fair value	$ 0	$ 0

FAIR VALUE MEASUREMENTS, Fair56

FAIR VALUE MEASUREMENTS, Fair value measures and impairments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Long-Lived Assets
Long-lived assets held and used, carrying value	$ 4		$ 4
Impairment long-lived assets held and used	4	$ 0	4	$ 0
Long-lived assets held and used written down fair value	0		0
Impairment of long-lived assets held for sale	0	0	0	0
Investments
Impairment of Investments	$ 0	$ 0	$ 0	$ 0

DERIVATIVES (Details)

DERIVATIVES (Details) $ in Millions	Oct. 20, 2014USD ($)	Jul. 31, 2016USD ($)contracts	Jul. 31, 2015USD ($)	Jul. 31, 2016USD ($)contracts	Jul. 31, 2015USD ($)	Feb. 01, 2016USD ($)	Jul. 01, 2012USD ($)	Aug. 09, 2011USD ($)contracts	Nov. 25, 2008USD ($)contracts
Derivative Instruments and Hedging Activities Disclosure
Gain (loss) recognized in accumulated other comprehensive income (loss)		$ (9)		$ (18)
Aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position		$ 19		$ 19
Derivative Contracts
Foreign exchange forward contracts designated as cash flow hedge (in units) | contracts		73		73
Foreign exchange forward contracts not designated as hedges (in units) | contracts		156		156
Senior Notes 2020
Terminated Interest Rate Swaps
Number of Interest Rate Swap Contracts Designated as Fair Value Hedges Terminated (in units) | contracts								5
Notional Amount of Terminated Interest Rate Swaps								$ 500
Amount to be amortized on terminated interest rates swaps		$ 16		$ 16
Senior Notes 2017
Terminated Interest Rate Swaps
Number of Interest Rate Swap Contracts Designated as Fair Value Hedges Terminated (in units) | contracts									2
Notional Amount of Terminated Interest Rate Swaps									$ 400
Amount to be amortized on terminated interest rates swaps		1		1
Derivative Instruments and Hedging Activities Disclosure
Debt instrument face amount	$ 600	100		100
Amount of extinguishment of debt	$ 500
Treasury Lock | Senior Notes 2022 | Cash Flow Hedging
Derivative Instruments and Hedging Activities Disclosure
Notional amount of interest rate swap contract							$ 400
Remaining gain to be amortized on derivative		2		2
Interest Rate Swap [Member] | Cash Flow Hedging
Derivative Instruments and Hedging Activities Disclosure
Notional amount of interest rate swap contract						$ 300
Designated as Hedging Instrument | Accumulated Other Comprehensive Income (Loss) | Treasury Lock | Cash Flow Hedging
Derivative Instruments and Hedging Activities Disclosure
Gain (loss) recognized in accumulated other comprehensive income (loss)		(11)		(14)
Designated as Hedging Instrument | Accumulated Other Comprehensive Income (Loss) | Interest Rate Swap [Member] | Cash Flow Hedging
Derivative Instruments and Hedging Activities Disclosure
Gain (loss) recognized in accumulated other comprehensive income (loss)		$ 11	$ 0	$ 14	$ 0

DERIVATIVES, Disclosures and de

DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details) $ in Millions	Jul. 31, 2016USD ($)
Sell | Forward Contracts DKK | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	$ 42
Sell | Cash Flow Hedging | Forward Contracts USD
Derivative
Total notional amount	183
Sell | Euro | Forward Contracts DKK | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	64
Sell | Euro | Cash Flow Hedging | Forward Contracts USD
Derivative
Total notional amount	46
Sell | British Pound | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	0
Sell | British Pound | Forward Contracts DKK | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	4
Sell | British Pound | Cash Flow Hedging | Forward Contracts USD
Derivative
Total notional amount	34
Sell | Canadian Dollar | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	0
Sell | Canadian Dollar | Forward Contracts DKK | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	2
Sell | Canadian Dollar | Cash Flow Hedging | Forward Contracts USD
Derivative
Total notional amount	26
Sell | Australian Dollars | Forward Contracts DKK | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	4
Sell | Malaysian Ringgit | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	2
Sell | Japanese Yen | Forward Contracts DKK | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	3
Sell | Japanese Yen | Cash Flow Hedging | Forward Contracts USD
Derivative
Total notional amount	75
Sell | Other | Forward Contracts DKK | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	15
Sell | Other | Cash Flow Hedging | Forward Contracts USD
Derivative
Total notional amount	6
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	167
Buy | Euro | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	105
Buy | Australian Dollars | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	12
Buy | Australian Dollars | Cash Flow Hedging | Forward Contracts USD
Derivative
Total notional amount	4
Buy | Japanese Yen | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	21
Buy | United States of America, Dollars | Forward Contracts DKK | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	50
Buy | Other | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	$ 31

DERIVATIVES, Fair value of deri

DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($) $ in Millions	Jul. 31, 2016	Oct. 31, 2015
Derivative Fair Value by Balance Sheet Location
Total derivatives Asset	$ 5	$ 4
Total derivatives Liabilities	22	5
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Total derivatives Asset	3	2
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Total derivatives Liabilities	21	1
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Total derivatives Asset	3	2
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Total derivatives Liabilities	7	1
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Interest Rate Swap [Member] | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Total derivatives Asset	0	0
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Interest Rate Swap [Member] | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Total derivatives Liabilities	14	0
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Total derivatives Asset	2	2
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Total derivatives Liabilities	$ 1	$ 4

DERIVATIVES, Effect of derivati

DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Derivative
Gain (loss) recognized in accumulated other comprehensive income (loss)	$ (9)		$ (18)
Cash Flow Hedging | Cost of Sales
Derivative
Cash Flow Hedge Net Gain to be Reclassified within Twelve Months	3
Derivatives Not Designated as Hedging Instruments | Other income (expense)
Derivative
Gain (loss) recognized in other income (expense)	(2)	$ (3)	3	$ (20)
Foreign Exchange Contracts | Designated as Hedging Instrument | Cash Flow Hedging | Accumulated Other Comprehensive Income (Loss)
Derivative
Gain (loss) recognized in accumulated other comprehensive income (loss)	2	3	(4)	11
Foreign Exchange Contracts | Designated as Hedging Instrument | Cash Flow Hedging | Cost of Sales
Derivative
Gain reclassified from accumulated other comprehensive income (loss) into cost of sales	(2)	3	0	14
Interest Rate Swap [Member] | Designated as Hedging Instrument | Cash Flow Hedging | Accumulated Other Comprehensive Income (Loss)
Derivative
Gain (loss) recognized in accumulated other comprehensive income (loss)	11	$ 0	14	$ 0
Treasury Lock | Designated as Hedging Instrument | Cash Flow Hedging | Accumulated Other Comprehensive Income (Loss)
Derivative
Gain (loss) recognized in accumulated other comprehensive income (loss)	$ (11)		$ (14)

RETIREMENT PLANS AND POST RET61

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Curtailments and Settlements
Curtailments and settlements	$ 0	$ 0	$ 16	$ 0
Pensions (U.S. Plans)
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	0	6	12	18
Interest cost on benefit obligation	4	3	11	10
Expected return on plan assets	(6)	(7)	(18)	(21)
Amortization:
Actuarial losses	0	2	2	4
Prior service cost	0	(1)	(2)	(3)
Total net plan costs	(2)	3	5	8
Curtailments and Settlements
Curtailments and settlements	0		(16)
Pensions (Non-U.S. Plans)
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	5	4	14	12
Interest cost on benefit obligation	4	6	12	18
Expected return on plan assets	(11)	(10)	(33)	(31)
Amortization:
Actuarial losses	7	6	21	19
Prior service cost	0	0	0	0
Total net plan costs	5	6	14	18
United States Post-retirement Benefit Plan
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	0	1	0	3
Interest cost on benefit obligation	1	1	3	3
Expected return on plan assets	(2)	(2)	(5)	(6)
Amortization:
Actuarial losses	3	1	8	3
Prior service cost	(3)	(3)	(8)	(9)
Total net plan costs	$ (1)	$ (2)	$ (2)	$ (6)

RETIREMENT PLANS AND POST RET62

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Defined Benefit Plans Contributions
Curtailment gain			$ 15
Settlement gain			1
Pensions (U.S. Plans)
Defined Benefit Plans Contributions
Contributions to defined benefit plans			0	$ 15
Estimated future employer contributions in remainder of current fiscal year	$ 0
Pensions (Non-U.S. Plans)
Defined Benefit Plans Contributions
Contributions to defined benefit plans	6	$ 9	$ 19	$ 20
Estimated future employer contributions in remainder of current fiscal year	$ 6

WARRANTIES AND CONTINGENCIES (D

WARRANTIES AND CONTINGENCIES (Details) - USD ($) $ in Millions	9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015
Movement in Standard Product Warranty Accrual
Beginning balance at beginning of period	$ 31	$ 30
Accruals for warranties including change in estimate	41	38
Settlements made during the period	(36)	(39)
Ending balance at end of period	36	29
Standard Product Warranty Disclosure
Accruals for warranties due within one year	35	27
Accruals for warranties due after one year	1	2
Ending balance at end of period	$ 36	$ 29

SHORT-TERM DEBT Credit Facility

SHORT-TERM DEBT Credit Facility (Details) - USD ($) $ in Millions	Sep. 15, 2014	Jul. 31, 2016	Jun. 09, 2015
Line of Credit Facility
Credit facility limit increase			$ 300
Amount outstanding on credit facility		$ 235
Line of Credit
Line of Credit Facility
Initiation date of credit facility	Sep. 15, 2014
Expiration date of credit facility	Sep. 15, 2019
Credit faciity terms (in years)	five
Initial maximum borrowing capacity of credit facility	$ 400
New maximum borrowing capacity of credit facility		$ 700

LONG-TERM DEBT (Details)

LONG-TERM DEBT (Details) - USD ($) $ in Millions	Jul. 31, 2016	Oct. 31, 2015
Debt Instrument
Long-term debt	$ 1,597	$ 1,596
Interest Rate Swap	17	21
Carrying Value of Senior Notes	1,614	1,617
Senior Notes 2017
Debt Instrument
Long-term debt	100	100
Interest Rate Swap	1	2
Carrying Value of Senior Notes	101	102
Senior Notes 2020
Debt Instrument
Long-term debt	499	499
Interest Rate Swap	16	19
Carrying Value of Senior Notes	515	518
Senior Notes 2022
Debt Instrument
Long-term debt	400	399
Interest Rate Swap	0	0
Carrying Value of Senior Notes	400	399
Senior Notes 2023
Debt Instrument
Long-term debt	598	598
Interest Rate Swap	0	0
Carrying Value of Senior Notes	$ 598	$ 598

LONG-TERM DEBT LONG-TERM DEBT -

LONG-TERM DEBT LONG-TERM DEBT - Other Debt (Details) $ in Millions	Jul. 31, 2016USD ($)
Other Long-term Debt
Mortgage Loans on Real Estate	$ 38

STOCKHOLDERS' EQUITY - Stock Re

STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) - USD ($) shares in Millions, $ in Millions	Nov. 22, 2013	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015	May 28, 2015
Share repurchase program
Cost to repurchases shares of common stock under share repurchase program				$ 388	$ 267
2014 Share Repurchase Program
Share repurchase program
Share repurchase program authorized amount	$ 1,000
Maintain weighted average diluted shares count (in shares)	335
Cost to repurchases shares of common stock under share repurchase program			$ 267	$ 98
Number of shares repurchased (in shares)			6	2.4
2015 Repurchase Program
Share repurchase program
Share repurchase program authorized amount						$ 1,140
Cost to repurchases shares of common stock under share repurchase program		$ 94		$ 290
Number of shares repurchased (in shares)		2.2		7.3
Remaining authorized repurchase amount under share repurchase program		$ 850		$ 850

STOCKHOLDER"S EQUITY - Dividend

STOCKHOLDER"S EQUITY - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Dividends Paid
Aggregate amount of cash dividends paid	$ 37	$ 33	$ 112	$ 100
Cash dividends paid per common share	$ 0.115	$ 0.100	$ 0.345	$ 0.300

STOCKHOLDER'S EQUITY - Accumula

STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Beginning Balance	$ (299)		$ (391)
Other comprehensive income (loss), before reclassifications	(60)		39
Amounts reclassified out of accumulated other comprehensive income (loss)	9		6
Tax (expense) benefit	5		1
Other comprehensive income (loss)	(46)	$ (62)	46	$ (330)
Ending Balance	(345)		(345)
Foreign currency translation
Beginning balance	(100)		(189)
Other comprehensive income (loss) before reclassifications	(51)		45
Amounts reclassified out of accumulated other comprehensive income (loss)	0		0
Tax (expense) benefit	3	1	(4)	8
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(48)	(66)	41	(337)
Ending balance	(148)		(148)
Prior service credits
Beginning balance	150		161
Other comprehensive income (loss) before reclassifications	0		6
Amounts reclassified out of accumulated other comprehensive income (loss)	(3)	(4)	(26)	(12)
Tax (expense) benefit	1		7
Other comprehensive income (loss)	(2)	(3)	(13)	(8)
Ending balance	148		148
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), before Tax
Beginning balance	(344)		(365)
Other comprehensive income (loss) before reclassifications	0		6
Amounts reclassified out of accumulated other comprehensive income (loss)	10	9	32	26
Tax (expense) benefit	(2)		(9)
Other comprehensive income (loss)	8	$ 7	29	$ 17
Ending balance	(336)		(336)
Unrealized gains (losses) on derivatives
Beginning balance	(5)		2
Other comprehensive income (loss) before reclassifications	(9)		(18)
Amounts reclassified out of accumulated other comprehensive income (loss)	2		0
Tax (expense) benefit	3		7
Other comprehensive income (loss)	(4)		(11)
Ending balance	$ (9)		$ (9)

STOCKHOLDERS' EQUITY - Reclassi

STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives
Unrealized loss on derivative reclassified to cost of products	$ (2)
Unrealized gains on derivatives reclassified to cost of products		$ 3	$ 0	$ 14
Unrealized gains and (losses) on derivatives reclassified to cost of products, before tax	(2)	3	0	14
Reclassification of (gains) and losses into earnings related to derivative instruments, tax	1	(2)	0	(5)
Unrealized gains and (losses) on derivatives reclassified to cost of products, net of tax	(1)	1	0	9
Actuarial net loss	(10)	(9)	(32)	(26)
Prior service benefit	3	4	26	12
Actuarial net loss and prior service benefit reclassified, before tax	(7)	(5)	(6)	(14)
Tax on actuarial net loss and prior service benefit reclassified	1	1	(1)	2
Actuarial net loss and prior service benefit reclassified, net of tax	(6)	(4)	(7)	(12)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	$ (7)	$ (3)	$ (7)	$ (3)

SEGMENT INFORMATION - Profitabi

SEGMENT INFORMATION - Profitability (Details) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016USD ($)	Jul. 31, 2015USD ($)	Jul. 31, 2016USD ($)	Jul. 31, 2015USD ($)
Segment Reporting [Abstract]
Number of operating segments	3
Select Income Statement Components
Total net revenue	$ 1,044	$ 1,014	$ 3,091	$ 3,003
Income from operations	146	144	432	366
Life Sciences and Applied Markets
Select Income Statement Components
Total net revenue	504	511	1,525	1,531
Income from operations	96	95	304	277
Diagnostics and Genomics
Select Income Statement Components
Total net revenue	180	167	516	484
Income from operations	34	28	76	54
Agilent CrossLab
Select Income Statement Components
Total net revenue	360	336	1,050	988
Income from operations	82	76	232	213
Segment Total
Select Income Statement Components
Total net revenue	1,044	1,014	3,091	3,003
Income from operations	$ 212	$ 199	$ 612	$ 544

SEGMENT INFORMATION - Reconcili

SEGMENT INFORMATION - Reconciliation of Reportable Results (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2016	Jul. 31, 2015
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
Total reportable segments’ income from operations	$ 212	$ 199	$ 612	$ 544
Acceleration of share-based compensation related to workforce reduction	0	0	0	(2)
Asset impairments	(4)	0	(4)	0
Transformational initiatives	(11)	(12)	(32)	(41)
Amortization of intangibles	(37)	(38)	(120)	(119)
Acquisition and integration costs	(11)	(4)	(28)	(6)
Business exit and divestiture costs (primarily our NMR business)	(1)	0	(7)	(11)
Pension curtailment gain	0	0	16	0
Other	(2)	(1)	(5)	1
Interest income	3	2	8	6
Interest expense	(17)	(17)	(53)	(50)
Other income (expense), net	2	(1)	6	15
Income from continuing operations before taxes	$ 134	$ 128	$ 393	$ 337

SEGMENT INFORMATION - Segment A

SEGMENT INFORMATION - Segment Assets (Details) - USD ($) $ in Millions	Jul. 31, 2016	Oct. 31, 2015
Segment Reporting Information
Assets	$ 7,734	$ 7,479
Life Sciences and Applied Markets
Segment Reporting Information
Assets	1,676	1,539
Diagnostics and Genomics
Segment Reporting Information
Assets	1,988	2,027
Agilent CrossLab
Segment Reporting Information
Assets	1,057	1,008
Segment Total
Segment Reporting Information
Assets	$ 4,721	$ 4,574

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) $ in Millions	Aug. 01, 2016USD ($)
iLabs Solutions [Member] | Subsequent Event
Acquisition
Purchase price of acquisition	$ 26